id,patient_id,referenceGenome,hugoSymbol,entrezGeneId,alteration,alterationType,svType,tumorType,consequence,proteinStart,proteinEnd,hgvs,geneExist,variantExist,alleleExist,oncogenic,mutationEffectDescription,knownEffect,citationPMids,citationAbstracts,highestSensitiveLevel,highestResistanceLevel,highestDiagnosticImplicationLevel,highestPrognosticImplicationLevel,highestFdaLevel,otherSignificantSensitiveLevels,otherSignificantResistanceLevels,hotspot,geneSummary,variantSummary,tumorTypeSummary,prognosticSummary,diagnosticSummary,diagnosticImplications,prognosticImplications,treatments,dataVersion,lastUpdate,vus,sample_id
495635,253,,MET,4233,Amplification,,,HGSOC,,,,,,,,Oncogenic,"MET amplification results from the gain of the MET gene on chromosome 7q31 and is found in various cancers, including melanoma, lung and renal cancers (PMID: 28481359). Often, this amplification leads to overexpression of the MET protein, which has been demonstrated to contribute to tumorigenesis by increasing downstream pathway activation, proliferation, invasiveness, and angiogenesis (PMID: 16461907, 18077425, 17463250, 19117057, 22869872,17667909). MET amplification has also been shown to contribute to resistance to tyrosine kinase inhibitors, including gefitinib and erlotinib and more recently osimertinib, as shown by sustained pathway activation and proliferation in the presence of drug (PMID: 18093943, 17463250, 30073261). In vitro proliferation assays of cell lines with MET amplifications show sensitivity to the MET-specific kinase inhibitor, PHA-665752 (PMID: 17463250, 16461907).",Gain-of-function,"30073261,16461907,19117057,17667909,22869872,18077425,18093943,28481359,17463250",[],LEVEL_3B,,,,LEVEL_Fda3,[],[],,"MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and rarely altered by gene translocation in various cancer types.",MET amplification is known to be oncogenic.,"While crizotinib is NCCN-compendium listed for the treatment of patients with high-level MET-amplified non-small cell lung cancer, its clinical utility in patients with MET-amplified high-grade serous ovarian cancer is unknown.",,,[],[],Crizotinib;Telisotuzumab Vedotin;Capmatinib;Tepotinib,v4.10,2023-02-27 00:00:00,,H115_pOvaL1_DNA1
495636,253,,BRAF,673,Amplification,,,HGSOC,,,,,,,,Oncogenic,"BRAF amplification is a rare event in cancer and has been found to occur at very low frequency in melanoma and glioma (cBioPortal, MSKCC, April 2017). It has been demonstrated that amplification of wildtype BRAF in melanoma cells leads to overexpression of the protein and constitutive activation of MAPK pathway, demonstrated as a BRAF-dependent increase in ERK phosphorylation, as well as an increase in cell proliferation (PMID: 15467732). BRAF overexpression has been associated with increased proliferation in gliomas (PMID: 25618114). Amplification of BRAF V600E allele has been described as a mechanism of resistance to MEK/RAF inhibitors in melanoma via MAPK pathway hyperactivation (PMID: 22395615, 24055054, 21098728).",Gain-of-function,"24055054,25618114,22395615,21098728,15467732",[],,,,,,[],[],,"BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers among others.",BRAF amplification is known to be oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRAF-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2023-06-22 00:00:00,,H115_pOvaL1_DNA1
495637,253,,EZH2,2146,Amplification,,,HGSOC,,,,,,,,Oncogenic,"EZH2 amplification results in overexpression of the protein. This alteration has been found in several tumor types and has been implicated as a marker of poor prognosis in various solid tumors (PMID: 12374981, 14500907, 21837672, 16330673, 16330673). EZH2 overexpression in natural killer and natural killer T-cell lymphoma cell lines resulted in a growth advantage compared to wildtype (PMID: 23529930).",Gain-of-function,"16330673,12374981,23529930,14500907,21837672",[],,,,,,[],[],,"EZH2, an epigenetic modifier, is altered by mutation and/or overexpression in solid tumors and hematologic malignancies.",EZH2 amplification is known to be oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EZH2-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2020-11-16 00:00:00,,H115_pOvaL1_DNA1
495638,253,,CDKN2A,1029,Deletion,,,HGSOC,,,,,,,,Oncogenic,"Deletion of CDKN2A results in loss of the p16/INK4A and p14/ARF proteins. CDKN2A deletion has been found in head and neck squamous cell carcinoma, glioma, bladder carcinoma, leukemia and melanoma and is often associated with poorer clinical outcomes (PMID: 15495191, 26516359, 10999737). Deletion of CDKN2A in mouse models of malignant mesothelioma resulted in accelerated tumorigenesis compared to wildtype (PMID: 21526190). In addition, knockdown of CDKN2A in an HRAS G12V mouse model resulted in the induction of high-grade endometrial stromal sarcoma (PMID: 28982163).",Loss-of-function,"21526190,28982163,26516359,15495191,10999737",[],LEVEL_4,,,,LEVEL_Fda3,[],[],,"The CDKN2A gene encodes two proteins, p16INK4A and p14ARF, that regulate the cell growth and survival. CDKN2A is altered by mutation and/or deletion in a broad range of solid and hematologic cancers.",CDKN2A deletion is known to be oncogenic.,"Laboratory data suggest that cancer cells with loss-of-function alterations of CDKN2A may be sensitive to CDK4/6 inhibitors such as palbociclib, ribociclib and abemaciclib.",,,[],[],Palbociclib;Ribociclib;Abemaciclib,v4.10,2023-02-15 00:00:00,,H115_pOvaL1_DNA1
495639,253,,ETV6,2120,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"ETV6, a transcription factor, is frequently altered by chromosomal rearrangement in hematologic malignancies.","ETV6 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ETV6-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,H115_pOvaL1_DNA1
495640,253,,ETNK1,55500,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"ETNK1, a kinase involved in phospholipid biosynthesis, is recurrently altered by mutation in BCR-ABL negative CML and CMML.","ETNK1 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ETNK1-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-08-01 00:00:00,,H115_pOvaL1_DNA1
495641,253,,KRAS,3845,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"KRAS amplification results in overexpression of the protein. This mutation has been found in germ cell tumors and esophagogastric and ovarian cancer (cBioPortal, Zehir, A et al. Nature Medicine, 2017). In vitro studies have demonstrated that this mutation confers resistance to the tyrosine kinase inhibitor crizotinib, EGFR inhibitors cetuximab or panitumumab, MET inhibitors PHA-665752 or JNJ38877605 and MEK inhibitors AZD6244 or GSK1120212 in patient-derived lung cancer cell line and xenograft models, colorectal cancer cell line models, MET-amplified cell line models and gastric cancer cell line models (PMID: 29808010, 30072474, 23404247, 20841479). Analyses of 475 patients with endometrial cancer demonstrated that KRAS amplification is associated with metastasis (PMID: 23099803).",Likely Gain-of-function,"23099803,29808010,30072474,20841479,23404247",[],,,,,,[],[],,"KRAS, a GTPase which functions as an upstream regulator of the MAPK pathway, is frequently mutated in various cancer types including lung, colorectal and pancreatic cancers.",KRAS amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KRAS-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2021-11-18 00:00:00,,H115_pOvaL1_DNA1
495642,253,,NTRK3,4916,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"NTRK3, a receptor tyrosine kinase, is altered by gene fusion in various cancer types.","NTRK3 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NTRK3-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2021-02-17 00:00:00,,H115_pOvaL1_DNA1
495643,253,,IDH2,3418,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"IDH2, a cell metabolism enzyme, is recurrently mutated in various cancer types including acute myeloid leukemia, glioblastoma, and cholangiocarcinoma.","IDH2 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IDH2-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-04 00:00:00,,H115_pOvaL1_DNA1
495644,253,,MAF,4094,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"MAF, a transcription factor, is recurrently altered by rearrangement in multiple myeloma.","MAF amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAF-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-30 00:00:00,,H115_pOvaL1_DNA1
495645,253,,BRCA1,672,Y1463*,,,HGSOC,stop_gained,1463,1463,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in BRCA1 is: Truncating mutations in BRCA1 can lead to varying C-terminally truncated proteins that results in aberrant protein folding, contributing to loss of BRCA1 protein function. Human breast cancer cell lines that contain a truncating mutation in BRCA1 display elevated levels of aneuploidy and impaired DNA damage response. In addition, truncating mutations have been shown to induce aberrant protein localization, which may impact the interaction of important binding partners (PMID: 20608970). Mouse models of BRCA1 truncating mutations develop cancer, including mammary carcinomas, lymphomas and ovarian carcinomas (PMID: 11358863, 12483515, 12947386).",Likely Loss-of-function,"11358863,20608970,12483515,12947386",[],LEVEL_1,,,,LEVEL_Fda2,[],[],,"BRCA1, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.","The BRCA1 Y1463* is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.","The PARP inhibitors olaparib, rucaparib and niraparib are FDA-approved for the treatment of patients with ovarian, fallopian tube, and primary peritoneal cancer with deleterious germline or somatic BRCA1 or 2 mutations (olaparib and niraparib are also approved for suspected deleterious mutations in this setting).",,,[],[],Olaparib;Rucaparib;Niraparib;Talazoparib,v4.10,2023-07-05 00:00:00,,H115_BDNA8794
495649,253,,TP53,7157,X125_splice,,,HGSOC,splice_region_variant,125,125,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in TP53 is: Truncating mutations of TP53 occur throughout the gene and lead to the production of several C-terminally truncated protein forms. These alterations are predicted to be inactivating and are associated with poor prognosis (PMID: 11900253, 11753428, 16007150, 21467160, 19336573). Experimental studies have revealed that truncating mutations promote cancer cell proliferation, survival and metastasis, since ectopic expression of these mutations in melanoma cells increased cell motility and tumor formation in vivo. This was due in part to aberrant localization of truncated proteins to the mitochondria, regulating genes involved in cell survival, including CypD (PMID: 27759562).",Likely Loss-of-function,"19336573,27759562,16007150,11753428,11900253,21467160",[],,,,,,[],[],,"TP53, a tumor suppressor in the DNA damage pathway, is the most frequently mutated gene in cancer.","There is no available functional data about the TP53 X125_splice alteration (last reviewed on 01/24/2023). However, it has been identified as a statistically significant hotspot and is likely to be oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP53 X125_splice altered high-grade serous ovarian cancer.,,,[],[],,v4.10,2023-01-24 00:00:00,,H115_BDNA8794
495653,253,,BCOR,54880,S1704Kfs*16,,,HGSOC,frameshift_variant,1703,1703,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in BCOR is: Truncating mutations in BCOR occur as both germline (oculofaciocardiodental or OFCD syndrome) and somatic (acute myeloid leukemia (AML) myelodysplastic syndrome, retinoblastoma) mutations in human disease, leading to reduced protein expression (PMID: 22012066, 24047651, 25550361, 22237022). Experimental studies using AML patient samples suggest loss of BCOR protein enhances cell proliferation and myeloid differentiation (PMID: 26847029).",Likely Loss-of-function,"26847029,22012066,25550361,22237022,24047651",[],,,,,,[],[],,"BCOR, a transcriptional repressor, is altered in various solid and hematologic malignancies including acute myeloid leukemia.","The BCOR S1704Kfs*16 is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCOR S1704Kfs*16 mutant high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-30 00:00:00,,H115_BDNA8794
495657,381,,FGFR1,2260,Amplification,,,HGSOC,,,,,,,,Oncogenic,"FGFR1 amplification results in overexpression of the protein. This mutation has been found in squamous cell lung, bladder and breast cancer (PMID: 22960745, 26451490, 24476821). In vitro studies demonstrate that FGFR1 overexpression in breast cancer cell lines promotes resistance to the ESR1 inhibitor fulvestrant as measured by sustained cell viability upon drug treatment (PMID: 31371343). A patient with FGFR1-amplified small cell lung cancer had a partial response to the FGFR-inhibitor pazopanib (Abstract: Russo et al. JCO PO, 2019. https://ascopubs.org/doi/full/10.1200/PO.19.00243).",Gain-of-function,"31371343,22960745,24476821,26451490","[{'link': 'https://ascopubs.org/doi/full/10.1200/PO.19.00243', 'abstract': 'Russo et al. JCO PO, 2019'}]",LEVEL_3B,,,,LEVEL_Fda3,[],[],,"FGFR1, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancer types including lung and breast cancers.",FGFR1 amplification is known to be oncogenic.,"While there is promising clinical data supporting the use of pan-FGFR-targeted inhibitors such as erdafitinib in patients with high-level FGFR1-amplified squamous cell lung cancer, their clinical utility in patients with FGFR1-amplified high-grade serous ovarian cancer is unknown.",,,[],[],Erdafitinib,v4.10,2023-06-21 00:00:00,,H243_pAdnR1_DNA1
495658,381,,MYC,4609,Amplification,,,HGSOC,,,,,,,,Oncogenic,"Amplification of MYC is correlated with an increase in the expression of the MYC gene (PMID: 22464321,15083194), which leads to the transcriptional activation of MYC target genes. MYC target genes regulate various cellular processes involved in oncogenesis including proliferation, inhibiting exit from the cell cycle, stimulating vascularization and enhancing genomic instability (PMID: 22464321,10378696,16934487,19029958). Genomic amplification of MYC is observed in a large number of tumor types. A study of genomic amplification across many cancer types identified focal amplifications of MYC in 14% of all cancers, with additional enrichment for large scale arm-level copy number alterations encompassing the MYC gene locus (PMID: 20164920).",Gain-of-function,"20164920,16934487,10378696,15083194,19029958,22464321",[],,,,,,[],[],,"MYC, a transcription factor, is altered by chromosomal rearrangement, amplification and overexpression in a variety of cancer types.",MYC amplification is known to be oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MYC-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-08-28 00:00:00,,H243_pAdnR1_DNA1
495659,381,,FGFR1,2260,Amplification,,,HGSOC,,,,,,,,Oncogenic,"FGFR1 amplification results in overexpression of the protein. This mutation has been found in squamous cell lung, bladder and breast cancer (PMID: 22960745, 26451490, 24476821). In vitro studies demonstrate that FGFR1 overexpression in breast cancer cell lines promotes resistance to the ESR1 inhibitor fulvestrant as measured by sustained cell viability upon drug treatment (PMID: 31371343). A patient with FGFR1-amplified small cell lung cancer had a partial response to the FGFR-inhibitor pazopanib (Abstract: Russo et al. JCO PO, 2019. https://ascopubs.org/doi/full/10.1200/PO.19.00243).",Gain-of-function,"31371343,22960745,24476821,26451490","[{'link': 'https://ascopubs.org/doi/full/10.1200/PO.19.00243', 'abstract': 'Russo et al. JCO PO, 2019'}]",LEVEL_3B,,,,LEVEL_Fda3,[],[],,"FGFR1, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancer types including lung and breast cancers.",FGFR1 amplification is known to be oncogenic.,"While there is promising clinical data supporting the use of pan-FGFR-targeted inhibitors such as erdafitinib in patients with high-level FGFR1-amplified squamous cell lung cancer, their clinical utility in patients with FGFR1-amplified high-grade serous ovarian cancer is unknown.",,,[],[],Erdafitinib,v4.10,2023-06-21 00:00:00,,H243_pOme1_DNA1
495660,381,,MYC,4609,Amplification,,,HGSOC,,,,,,,,Oncogenic,"Amplification of MYC is correlated with an increase in the expression of the MYC gene (PMID: 22464321,15083194), which leads to the transcriptional activation of MYC target genes. MYC target genes regulate various cellular processes involved in oncogenesis including proliferation, inhibiting exit from the cell cycle, stimulating vascularization and enhancing genomic instability (PMID: 22464321,10378696,16934487,19029958). Genomic amplification of MYC is observed in a large number of tumor types. A study of genomic amplification across many cancer types identified focal amplifications of MYC in 14% of all cancers, with additional enrichment for large scale arm-level copy number alterations encompassing the MYC gene locus (PMID: 20164920).",Gain-of-function,"20164920,16934487,10378696,15083194,19029958,22464321",[],,,,,,[],[],,"MYC, a transcription factor, is altered by chromosomal rearrangement, amplification and overexpression in a variety of cancer types.",MYC amplification is known to be oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MYC-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-08-28 00:00:00,,H243_pOme1_DNA1
495661,381,,JAK2,3717,Amplification,,,HGSOC,,,,,,,,Oncogenic,"Chromosome 9p24.1 has been shown to include JAK2 as well as the programmed cell death-1 (PD1) ligand genes, PD-L1 and PD-L2; its amplification is often detected in Classical Hodgkin lymphoma (cHL) and mediastinal large B-cell lymphoma (MLBCL). Amplification of 9p24.1 was associated with increased protein expression and activity as well as increased PD-1 ligand transcription and enhanced sensitivity to JAK2 inhibition (PMID: 20628145).",Gain-of-function,20628145,[],,,,,,[],[],,"JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematologic malignancies.",JAK2 amplification is known to be oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK2-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2021-10-05 00:00:00,,H243_pOme1_DNA1
495662,381,,CD274,29126,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"Amplification of CD274 (more commonly PD-L1) has been detected across several tumor types including Hodgkin's lymphoma (HL), mediastinal large B-cell lymphoma (MLBCL), small cell lung cancer, among others (PMID: 20628145, 29902298, 29377256, 27069084, 27620277). In preclinical assays, cells overexpressing PD-L1 exhibit increased features of immune evasion, due to binding of the PD-1 cell surface receptor expressed on immune cells (PMID: 28302645). In addition, the tyrosine kinase JAK2 is included in the 9p24.1 amplification region of PD-L1, which can also activate transcription of PD-L1 (PMID: 20628145). Preclinical studies have demonstrated that HL cells with PD-L1 amplification are sensitive to JAK2 inhibition (PMID: 24610827, 29467301). Patients with PD-L1 amplification have been found to have objective responses to PD-1/PD-L1-targeted immune therapies (PMID: 29902298, 28356247).",Likely Gain-of-function,"28302645,29377256,20628145,29902298,27069084,28356247,24610827,29467301,27620277",[],,,,,,[],[],,"CD274 (also known as PD-L1) is an immune receptor ligand. Expression of PD-L1 may help predict response to immunotherapies targeted against PD-L1 and its receptor, PD-1.",CD274 amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CD274-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-16 00:00:00,,H243_pOme1_DNA1
495663,381,,PDCD1LG2,80380,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"Amplification of PDCD1LG2 has been detected across several tumor types including Hodgkin's lymphoma and mediastinal large B-cell lymphoma (PMID: 27069084, 29377256, 26850007, 26317899). In biochemical assays, cells overexpressing PDCD1LG2 demonstrate increased features of immune evasion from binding of the PD-1 cell surface receptor expressed on immune cells (PMID: 29167175). In addition, the tyrosine kinase JAK2 and PDCD1LG1 are included in the 9p24.1 amplification region of PDCD1LG2 (PMID: 20628145). Preclinical studies have demonstrated that cHL and MLBCL cell lines with PDCD1LG2 amplification are sensitive to JAK2 inhibition as measured by decreased tumor growth and prolonged survival (PMID: 24610827, 29467301). Patients with PDCD1LG2 amplification have been found to have an objective response to PD-1/PD-L1-targeted immune therapies (PMID: 29902298, 28356247).",Likely Gain-of-function,"29377256,20628145,29902298,27069084,26850007,28356247,24610827,29467301,29167175,26317899",[],,,,,,[],[],,"PDCD1LG2, a ligand of T-cell receptors involved in immune suppression, is overexpressed in various cancer types.",PDCD1LG2 amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PDCD1LG2-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2023-01-11 00:00:00,,H243_pOme1_DNA1
495664,381,,CDKN2A,1029,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"The CDKN2A gene encodes two proteins, p16INK4A and p14ARF, that regulate the cell growth and survival. CDKN2A is altered by mutation and/or deletion in a broad range of solid and hematologic cancers.","CDKN2A amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CDKN2A-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-05-31 00:00:00,,H243_pOme1_DNA1
495665,381,,PIK3CA,5290,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"PIK3CA amplification is an infrequent event across cancers (PMID: 28481359), although several individual studies have reported them in lung squamous cell carcinoma, ovarian, esophagus, cervical, and head and neck tumors (PMID: 22960745, 21720365, 25631445, 23636398). PIK3CA gene amplification has been correlated with PIK3CA protein overexpression (PMID: 17992665,19697359). PIK3CA overexpression enhances growth and migration (PMID: 17803655, 26876212). PIK3CA amplifications associate with poor prognosis in several cancers (PMID: 22994622, 22292935, 27095573). Some studies have found a correlation between PIK3CA copy number amplification and sensitivity to PI3K inhibitors (PMID: 24608574, 23136191). Amplification of PIK3CA known pathogenic mutant alleles have also been reported (PMID: 19706770). Expression of this mutation in a patient-derived xenograft model of lung squamous cell carcinoma demonstrated that it was not sensitive to the pan-PIK3CA inhibitor BKM120 similar to PDX models expressing wildtype PIK3CA (PMID: 30093452).",Likely Gain-of-function,"21720365,22960745,17992665,23136191,30093452,19706770,28481359,22292935,22994622,19697359,25631445,24608574,26876212,23636398,27095573,17803655",[],,,,,,[],[],,"PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers.",PIK3CA amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CA-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-04-18 00:00:00,,H243_pOvaL1_DNA1
495666,381,,BCL6,604,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"The amplification of BCL6 has been observed across a range of tumor types. Specifically, in follicular lymphoma BCL6 amplification was observed in a cohort of tumors lacking otherwise typical IGH/BCL2 rearrangements (PMID: 18500267, 24887414). BCL6 is a transcriptional regulator in germinal centers, from which human lymphomas often derive. In model systems, overexpression of BCL6 results in an anti-apoptotic and chemotherapy resistant phenotype (PMID: 15577913, 16142238).",Likely Gain-of-function,"16142238,18500267,24887414,15577913",[],,,,,,[],[],,"BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas.",BCL6 amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,H243_pOvaL1_DNA1
495667,381,,TP63,8626,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"TP63, a transcription factor, is recurrently altered by chromosomal rearrangement in hematologic malignancies.","TP63 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP63-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,H243_pOvaL1_DNA1
495668,381,,IL7R,3575,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"IL7R, a subunit of the interleukin 7 receptor, is altered in various hematologic malignancies including pediatric acute lymphoblastic leukemia.","IL7R amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IL7R-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-07-30 00:00:00,,H243_pOvaL1_DNA1
495669,381,,FGFR1,2260,Amplification,,,HGSOC,,,,,,,,Oncogenic,"FGFR1 amplification results in overexpression of the protein. This mutation has been found in squamous cell lung, bladder and breast cancer (PMID: 22960745, 26451490, 24476821). In vitro studies demonstrate that FGFR1 overexpression in breast cancer cell lines promotes resistance to the ESR1 inhibitor fulvestrant as measured by sustained cell viability upon drug treatment (PMID: 31371343). A patient with FGFR1-amplified small cell lung cancer had a partial response to the FGFR-inhibitor pazopanib (Abstract: Russo et al. JCO PO, 2019. https://ascopubs.org/doi/full/10.1200/PO.19.00243).",Gain-of-function,"31371343,22960745,24476821,26451490","[{'link': 'https://ascopubs.org/doi/full/10.1200/PO.19.00243', 'abstract': 'Russo et al. JCO PO, 2019'}]",LEVEL_3B,,,,LEVEL_Fda3,[],[],,"FGFR1, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancer types including lung and breast cancers.",FGFR1 amplification is known to be oncogenic.,"While there is promising clinical data supporting the use of pan-FGFR-targeted inhibitors such as erdafitinib in patients with high-level FGFR1-amplified squamous cell lung cancer, their clinical utility in patients with FGFR1-amplified high-grade serous ovarian cancer is unknown.",,,[],[],Erdafitinib,v4.10,2023-06-21 00:00:00,,H243_pOvaL1_DNA1
495670,381,,MDM2,4193,Amplification,,,HGSOC,,,,,,,,Oncogenic,"MDM2 amplification results from the gain of the MDM2 gene on chromosome 12q13-15 and is found in a variety of cancers. Often, this amplification leads to overexpression of the MDM2 protein, which has been demonstrated to contribute to tumorigenesis by impairing TP53-mediated tumor suppressor effects in the context of wildtype TP53 (PMID: PMID: 15199139, 24667108).",Gain-of-function,"15199139,24667108",[],,,,,,[],[],,"MDM2, a ubiquitin ligase and p53 inhibitor, is amplified in a diverse range of cancers including well-differentiated liposarcomas.",MDM2 amplification is known to be oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MDM2-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-04-05 00:00:00,,H243_pOvaL1_DNA1
495671,381,,SETBP1,26040,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"SETBP1, an epigenetic remodeling protein, is frequently altered by mutation in a range of hematopoietic malignancies.","SETBP1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SETBP1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-08-23 00:00:00,,H243_pOvaL1_DNA1
495672,381,,PIK3CA,5290,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"PIK3CA amplification is an infrequent event across cancers (PMID: 28481359), although several individual studies have reported them in lung squamous cell carcinoma, ovarian, esophagus, cervical, and head and neck tumors (PMID: 22960745, 21720365, 25631445, 23636398). PIK3CA gene amplification has been correlated with PIK3CA protein overexpression (PMID: 17992665,19697359). PIK3CA overexpression enhances growth and migration (PMID: 17803655, 26876212). PIK3CA amplifications associate with poor prognosis in several cancers (PMID: 22994622, 22292935, 27095573). Some studies have found a correlation between PIK3CA copy number amplification and sensitivity to PI3K inhibitors (PMID: 24608574, 23136191). Amplification of PIK3CA known pathogenic mutant alleles have also been reported (PMID: 19706770). Expression of this mutation in a patient-derived xenograft model of lung squamous cell carcinoma demonstrated that it was not sensitive to the pan-PIK3CA inhibitor BKM120 similar to PDX models expressing wildtype PIK3CA (PMID: 30093452).",Likely Gain-of-function,"21720365,22960745,17992665,23136191,30093452,19706770,28481359,22292935,22994622,19697359,25631445,24608574,26876212,23636398,27095573,17803655",[],,,,,,[],[],,"PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers.",PIK3CA amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CA-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-04-18 00:00:00,,H243_pPer1_DNA1
495673,381,,BCL6,604,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"The amplification of BCL6 has been observed across a range of tumor types. Specifically, in follicular lymphoma BCL6 amplification was observed in a cohort of tumors lacking otherwise typical IGH/BCL2 rearrangements (PMID: 18500267, 24887414). BCL6 is a transcriptional regulator in germinal centers, from which human lymphomas often derive. In model systems, overexpression of BCL6 results in an anti-apoptotic and chemotherapy resistant phenotype (PMID: 15577913, 16142238).",Likely Gain-of-function,"16142238,18500267,24887414,15577913",[],,,,,,[],[],,"BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas.",BCL6 amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,H243_pPer1_DNA1
495674,381,,TP63,8626,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"TP63, a transcription factor, is recurrently altered by chromosomal rearrangement in hematologic malignancies.","TP63 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP63-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,H243_pPer1_DNA1
495675,381,,FBXW7,55294,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"FBXW7, a tumor suppressor involved in protein degradation, is inactivated by mutation in various cancer types, most frequently in endometrial and colorectal cancers.","FBXW7 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FBXW7-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-11-01 00:00:00,,H243_pPer1_DNA1
495676,381,,FGFR1,2260,Amplification,,,HGSOC,,,,,,,,Oncogenic,"FGFR1 amplification results in overexpression of the protein. This mutation has been found in squamous cell lung, bladder and breast cancer (PMID: 22960745, 26451490, 24476821). In vitro studies demonstrate that FGFR1 overexpression in breast cancer cell lines promotes resistance to the ESR1 inhibitor fulvestrant as measured by sustained cell viability upon drug treatment (PMID: 31371343). A patient with FGFR1-amplified small cell lung cancer had a partial response to the FGFR-inhibitor pazopanib (Abstract: Russo et al. JCO PO, 2019. https://ascopubs.org/doi/full/10.1200/PO.19.00243).",Gain-of-function,"31371343,22960745,24476821,26451490","[{'link': 'https://ascopubs.org/doi/full/10.1200/PO.19.00243', 'abstract': 'Russo et al. JCO PO, 2019'}]",LEVEL_3B,,,,LEVEL_Fda3,[],[],,"FGFR1, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancer types including lung and breast cancers.",FGFR1 amplification is known to be oncogenic.,"While there is promising clinical data supporting the use of pan-FGFR-targeted inhibitors such as erdafitinib in patients with high-level FGFR1-amplified squamous cell lung cancer, their clinical utility in patients with FGFR1-amplified high-grade serous ovarian cancer is unknown.",,,[],[],Erdafitinib,v4.10,2023-06-21 00:00:00,,H243_pPer1_DNA1
495677,381,,MYC,4609,Amplification,,,HGSOC,,,,,,,,Oncogenic,"Amplification of MYC is correlated with an increase in the expression of the MYC gene (PMID: 22464321,15083194), which leads to the transcriptional activation of MYC target genes. MYC target genes regulate various cellular processes involved in oncogenesis including proliferation, inhibiting exit from the cell cycle, stimulating vascularization and enhancing genomic instability (PMID: 22464321,10378696,16934487,19029958). Genomic amplification of MYC is observed in a large number of tumor types. A study of genomic amplification across many cancer types identified focal amplifications of MYC in 14% of all cancers, with additional enrichment for large scale arm-level copy number alterations encompassing the MYC gene locus (PMID: 20164920).",Gain-of-function,"20164920,16934487,10378696,15083194,19029958,22464321",[],,,,,,[],[],,"MYC, a transcription factor, is altered by chromosomal rearrangement, amplification and overexpression in a variety of cancer types.",MYC amplification is known to be oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MYC-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-08-28 00:00:00,,H243_pPer1_DNA1
495678,381,,TP53,7157,W53*,,,HGSOC,stop_gained,53,53,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in TP53 is: Truncating mutations of TP53 occur throughout the gene and lead to the production of several C-terminally truncated protein forms. These alterations are predicted to be inactivating and are associated with poor prognosis (PMID: 11900253, 11753428, 16007150, 21467160, 19336573). Experimental studies have revealed that truncating mutations promote cancer cell proliferation, survival and metastasis, since ectopic expression of these mutations in melanoma cells increased cell motility and tumor formation in vivo. This was due in part to aberrant localization of truncated proteins to the mitochondria, regulating genes involved in cell survival, including CypD (PMID: 27759562).",Likely Loss-of-function,"19336573,27759562,16007150,11753428,11900253,21467160",[],,,,,,[],[],,"TP53, a tumor suppressor in the DNA damage pathway, is the most frequently mutated gene in cancer.","The TP53 W53* is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP53 W53* mutant high-grade serous ovarian cancer.,,,[],[],,v4.10,2017-06-13 00:00:00,,H243_BDNA12455
495686,404,,IL7R,3575,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"IL7R, a subunit of the interleukin 7 receptor, is altered in various hematologic malignancies including pediatric acute lymphoblastic leukemia.","IL7R amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IL7R-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-07-30 00:00:00,,H266_p2Ome1_TR_DNA
495687,404,,ABL1,25,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"ABL1, a tyrosine kinase, is frequently altered by chromosomal translocations in leukemia.","ABL1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ABL1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2020-11-09 00:00:00,,H266_p2Ome1_TR_DNA
495688,404,,MAP2K1,5604,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"MAP2K1, an intracellular kinase, is mutated at low frequencies in various cancer types including melanoma, colorectal and lung cancers.","MAP2K1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAP2K1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-04 00:00:00,,H266_p2Ome1_TR_DNA
495689,404,,NTRK3,4916,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"NTRK3, a receptor tyrosine kinase, is altered by gene fusion in various cancer types.","NTRK3 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NTRK3 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2021-02-17 00:00:00,,H266_p2Ome1_TR_DNA
495690,404,,IDH2,3418,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"IDH2, a cell metabolism enzyme, is recurrently mutated in various cancer types including acute myeloid leukemia, glioblastoma, and cholangiocarcinoma.","IDH2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IDH2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-04 00:00:00,,H266_p2Ome1_TR_DNA
495691,404,,TP53,7157,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"TP53 deletions are predicted to be inactivating and associated with poor prognosis (PMID: 11900253, 20697090, 21467160, 12584563). Experimental studies have revealed that deletions result in loss of TP53 tumor suppressive function, since TP53 cannot decrease cell viability in vitro (PMID: 27759562). Additionally, deletion of TP53 in the neurons of mice, while not sufficient to cause tumor development, allows the accumulation of other oncogenic mutations leading to tumorigenesis (PMID: 19477430). Further, loss of TP53 protein during 17p deletion events in leukemia/lymphoma, enhances cancer development through cooperation of linked tumor suppressive genes such as EIF5A and ALOX15B (PMID: 26982726).",Likely Loss-of-function,"26982726,20697090,27759562,19477430,11900253,12584563,21467160",[],,,,,,[],[],,"TP53, a tumor suppressor in the DNA damage pathway, is the most frequently mutated gene in cancer.",TP53 deletion is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP53 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-07-18 00:00:00,,H266_p2Ome1_TR_DNA
495692,404,,TYK2,7297,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"TYK2, a non-receptor kinase, is infrequently altered by mutation and rearrangement in hematopoietic malignancies.","TYK2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TYK2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-08-23 00:00:00,,H266_p2Ome1_TR_DNA
495693,404,,EPOR,2057,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"EPOR, a cytokine receptor, is recurrently altered by chromosomal rearrangement in familial erythrocytosis and acute lymphoblastic leukemia.","EPOR deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPOR deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-17 00:00:00,,H266_p2Ome1_TR_DNA
495694,404,,ERCC2,2068,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in ERCC2 is: ERCC2 truncating mutations can produce several forms of C-terminally truncated proteins. These mutations have been found as germline mutations in skin, breast and ovarian cancer (PMID: 27504877). Expression of ERCC2 truncating mutations in a fibroblast cell line demonstrated that they are inactivating as measured by decreased DNA-damage repair and/or transcriptional activity compared to wildtype (PMID: 27504877).",Likely Loss-of-function,27504877,[],LEVEL_3B,,,,LEVEL_Fda3,[],[],,"ERCC2, a DNA helicase involved in the nucleotide excision repair (NER) pathway, is frequently altered in bladder cancer. Germline mutations of ERCC2 are associated with xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome, and predispose to certain cancers.","The ERCC2 Deletion is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.","While there is promising clinical data in patients with bladder cancer harboring oncogenic ERCC2 alterations treated with platinum-based chemotherapies such as cisplatin, their clinical utility in patients with ERCC2 deletion high-grade serous ovarian cancer is unknown.",,,[],[],Cisplatin,v4.10,2023-03-02 00:00:00,,H266_p2Ome1_TR_DNA
495695,404,,SMARCB1,6598,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"SMARCB1 deletions are associated with loss of the protein and are found primarily in malignant rhabdoid tumors (MRTs) (PMID:22797305,23074045). While homozygous deletions in mice are embryonic lethal, heterozygous SMARCB1 deletions can lead to numerous different types of cancers including rhabdoid tumors, and soft tissue sarcomas, often with biallelic loss of SMARCB1 (PMID:11263494,11313485,11095756,12450796). In humans, germline deletions and mutations in SMARCB1 are the basis for familial cancer syndromes (PMID:10521299,9892189).",Likely Loss-of-function,"11313485,10521299,11095756,23074045,9892189,12450796,22797305,11263494",[],LEVEL_3B,,,,LEVEL_Fda3,[],[],,"SMARCB1, a protein involved in chromatin remodeling, is inactivated by mutation or deletion in various cancer types including soft tissue sarcomas and CNS cancers.",SMARCB1 deletion is likely oncogenic.,"Loss of SMARCB1 function has been demonstrated to confer oncogenic dependence on EZH2 (PMID: 20951942). While the EZH2 inhibitor tazemetostat is FDA approved for the treatment of patients with epithelioid sarcoma (ES), the majority of whom have SMARCB1 deletion, its clinical utility in patients with other tumor types is unknown.",,,[],[],Tazemetostat,v4.10,2023-02-24 00:00:00,,H266_p2Ome1_TR_DNA
495696,404,,CHEK2,11200,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in CHEK2 is: CHEK2 is a tumor suppressor gene and truncating mutations are therefore considered to be likely oncogenic. Truncating mutations in CHEK2 have been associated with increased risk of breast, prostate and colorectal cancer in various populations (PMID: 19401704, 27464310, 28779002).",Likely Loss-of-function,"28779002,19401704,27464310",[],LEVEL_3B,,,,LEVEL_Fda3,[],[],,"CHEK2, a tumor suppressor and intracellular kinase, is altered in various cancer types. Germline mutations of CHEK2 are associated with an increased risk of certain cancers including breast, prostate and colorectal cancers.","The CHEK2 Deletion is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.","While the PARP inhibitors olaparib as a single agent and talazoparib in combination with enzalutamide are FDA-approved for the treatment of patients with metastatic castration-resistant prostate cancer with CHEK2 mutations, the clinical utility of these agents in patients with CHEK2 deletion high-grade serous ovarian cancer is unknown.",,,[],[],Olaparib;Talazoparib,v4.10,2023-07-11 00:00:00,,H266_p2Ome1_TR_DNA
495697,404,,PDGFB,5155,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"PDGFB, a growth factor that activates PDGFR signaling, is recurrently altered by rearrangement in dermatofibrosarcoma protuberans (DFSP), a sarcoma of the skin, and related diseases.","PDGFB deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PDGFB deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-05 00:00:00,,H266_p2Ome1_TR_DNA
495698,404,,EP300,2033,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"EP300 truncating mutations result in EP300 proteins that lack some or all of the key enzymatic domains: the histone acetyltransferase (HAT) domain, the bromodomain and transcription factor binding domains (PMID: 12402157). Functional studies have shown that deletion of these domains result in decreased acetyltransferase and tumor suppressive activity (PMID: 12237408). Deletion of one EP300 allele is highly associated with loss of the second EP300 allele (PMID: 10700188) and can lead to disruption of signaling cascades such as the TGFβ pathway (PMID: 12237408).",Likely Loss-of-function,"12237408,10700188,12402157",[],,,,,,[],[],,"EP300, a tumor suppressor and histone acetyltransferase, is inactivated in various cancer types.",EP300 deletion is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EP300 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-02-14 00:00:00,,H266_p2Ome1_TR_DNA
495699,404,,STAG2,10735,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"STAG2, a component of the cohesin complex, is recurrently altered by mutation in various cancer types,.","STAG2 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with STAG2-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-07-30 00:00:00,,H266_p2Ome1_TR_DNA
495700,404,,PHF6,84295,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"PHF6, a chromatin binding protein, is frequently altered by mutation and deletion in a range of hematologic malignancies.","PHF6 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PHF6-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-12-10 00:00:00,,H266_p2Ome1_TR_DNA
495701,404,,FGFR2,2263,P253R,,,HGSOC,missense_variant,253,253,,,,,Oncogenic,"The FGFR2 P253R mutation is located in the extracellular domain of the protein. This mutation is an autosomal dominant mutation associated with Apert syndrome, a severe craniosynostosis syndrome (PMID: 18552176). Expression of this mutation in NIH3T3 cells demonstrated that the is is likely activating as measured by an increased receptor affinity for fibroblast growth factor ligands (FGFs), leading to enhanced activation of the kinase compared to wildtype FGFR2 (PMID: 11121055, 24265351).",Gain-of-function,"18552176,24265351,11121055",[],LEVEL_4,,,,LEVEL_Fda3,[],[],,"FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancer types.",The FGFR2 P253R mutation is known to be oncogenic.,"Laboratory data suggest that cancer cells with certain oncogenic FGFR2 mutations may be sensitive to selective FGFR-targeted inhibitors such as RLY-4008, AZD4547 and erdafitinib.",,,[],[],Erdafitinib;RLY-4008;AZD4547,v4.10,2023-06-22 00:00:00,,H266_BDNA12951
495703,404,,TP53,7157,W53*,,,HGSOC,stop_gained,53,53,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in TP53 is: Truncating mutations of TP53 occur throughout the gene and lead to the production of several C-terminally truncated protein forms. These alterations are predicted to be inactivating and are associated with poor prognosis (PMID: 11900253, 11753428, 16007150, 21467160, 19336573). Experimental studies have revealed that truncating mutations promote cancer cell proliferation, survival and metastasis, since ectopic expression of these mutations in melanoma cells increased cell motility and tumor formation in vivo. This was due in part to aberrant localization of truncated proteins to the mitochondria, regulating genes involved in cell survival, including CypD (PMID: 27759562).",Likely Loss-of-function,"19336573,27759562,16007150,11753428,11900253,21467160",[],,,,,,[],[],,"TP53, a tumor suppressor in the DNA damage pathway, is the most frequently mutated gene in cancer.","The TP53 W53* is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP53 W53* mutant high-grade serous ovarian cancer.,,,[],[],,v4.10,2017-06-13 00:00:00,,H266_BDNA12951
495705,35,,PIK3CA,5290,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"PIK3CA amplification is an infrequent event across cancers (PMID: 28481359), although several individual studies have reported them in lung squamous cell carcinoma, ovarian, esophagus, cervical, and head and neck tumors (PMID: 22960745, 21720365, 25631445, 23636398). PIK3CA gene amplification has been correlated with PIK3CA protein overexpression (PMID: 17992665,19697359). PIK3CA overexpression enhances growth and migration (PMID: 17803655, 26876212). PIK3CA amplifications associate with poor prognosis in several cancers (PMID: 22994622, 22292935, 27095573). Some studies have found a correlation between PIK3CA copy number amplification and sensitivity to PI3K inhibitors (PMID: 24608574, 23136191). Amplification of PIK3CA known pathogenic mutant alleles have also been reported (PMID: 19706770). Expression of this mutation in a patient-derived xenograft model of lung squamous cell carcinoma demonstrated that it was not sensitive to the pan-PIK3CA inhibitor BKM120 similar to PDX models expressing wildtype PIK3CA (PMID: 30093452).",Likely Gain-of-function,"21720365,22960745,17992665,23136191,30093452,19706770,28481359,22292935,22994622,19697359,25631445,24608574,26876212,23636398,27095573,17803655",[],,,,,,[],[],,"PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers.",PIK3CA amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CA-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-04-18 00:00:00,,M035_pOvaR_DNA5
495706,35,,FGFR3,2261,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.","FGFR3 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR3-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2017-01-10 00:00:00,,M035_pOvaR_DNA5
495707,35,,NRG1,3084,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"NRG1, a ligand that binds HER3, is recurrently altered by fusions in lung, pancreatic, and other cancers.","NRG1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NRG1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2022-07-15 00:00:00,,M035_pOvaR_DNA5
495708,35,,GATA3,2625,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"GATA3 deletions have been detected in patients with breast cancer and commonly results in the production of truncated protein forms (PMID: 15361840). Experimental studies suggest that these mutations alter the cellular localization of the protein (PMID: 15361840), and affects DNA-binding and transactivation abilities (PMID: 7829479, 10935639, 24758297, 26637396) leading to increased cellular invasiveness.",Likely Loss-of-function,"10935639,15361840,26637396,24758297,7829479",[],,,,,,[],[],,"GATA3, a transcription factor, is altered by mutation or amplification in various cancers, most frequently in breast cancer.",GATA3 deletion is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GATA3 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-06-01 00:00:00,,M035_pOvaR_DNA5
495709,35,,HRAS,3265,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"HRAS amplification results in overexpression of the protein. This mutation has been found in thyroid, head and neck and small cell lung cancers (cBioPortal, MSKCC, April 2017). Overexpression of HRAS in a rat model of breast cancer and a mouse model of skin cancer demonstrated that this mutation is likely activating as measured by a correlation between increased expression of HRAS and disease progression (PMID: 1855225, 8221670). Overexpression of HRAS is suggested as a potential alternative mechanism for HRAS-mediated oncogenic transformation (PMID: 3283542, 3283542).",Likely Gain-of-function,"3283542,8221670,1855225",[],,,,,,[],[],,"HRAS, a GTPase, is altered in a diverse range of cancers including head and neck squamous cell carcinoma, thyroid, and bladder cancer.",HRAS amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HRAS-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2020-11-16 00:00:00,,M035_pOvaR_DNA5
495710,35,,ETNK1,55500,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"ETNK1, a kinase involved in phospholipid biosynthesis, is recurrently altered by mutation in BCR-ABL negative CML and CMML.","ETNK1 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ETNK1-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-08-01 00:00:00,,M035_pOvaR_DNA5
495711,35,,KRAS,3845,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"KRAS amplification results in overexpression of the protein. This mutation has been found in germ cell tumors and esophagogastric and ovarian cancer (cBioPortal, Zehir, A et al. Nature Medicine, 2017). In vitro studies have demonstrated that this mutation confers resistance to the tyrosine kinase inhibitor crizotinib, EGFR inhibitors cetuximab or panitumumab, MET inhibitors PHA-665752 or JNJ38877605 and MEK inhibitors AZD6244 or GSK1120212 in patient-derived lung cancer cell line and xenograft models, colorectal cancer cell line models, MET-amplified cell line models and gastric cancer cell line models (PMID: 29808010, 30072474, 23404247, 20841479). Analyses of 475 patients with endometrial cancer demonstrated that KRAS amplification is associated with metastasis (PMID: 23099803).",Likely Gain-of-function,"23099803,29808010,30072474,20841479,23404247",[],,,,,,[],[],,"KRAS, a GTPase which functions as an upstream regulator of the MAPK pathway, is frequently mutated in various cancer types including lung, colorectal and pancreatic cancers.",KRAS amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KRAS-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2021-11-18 00:00:00,,M035_pOvaR_DNA5
495712,35,,ERBB2,2064,Amplification,,,HGSOC,,,,,,,,Oncogenic,"ERBB2 amplification results in overexpression of the protein. Overexpression of ERBB2 in murine fibroblasts and in the mammary glands of genetically engineered mouse models have demonstrated that it is activating as measured by increased pathway activation and tumor growth (PMID: 23204226, 12124352, 11571643, 10716706, 2885917). In vitro studies have demonstrated that this mutation is sensitive to trastuzumab when expressed in biliary tract cancer cell lines as measured by decreased proliferation upon drug treatment (PMID: 30659304). One patient with biliary tract cancer overexpressing ERBB2 had a partial response to an ERBB2-targeting antibody linked to a cytotoxic agent, ado-trastuzumab emtansine (Abstract: Mondaca et al. JCO PO, 2019. https://ascopubs.org/doi/full/10.1200/PO.19.00223). The therapeutic agents trastuzumab, ado-trastuzumab emtansine, lapatinib and pertuzumab in combination with trastuzumab are FDA-approved drugs for the treatment of patients with ERBB2 amplified breast cancer. Trastuzumab is also FDA-approved for the treatment of patients with ERBB2-amplified gastric cancer.",Gain-of-function,"30659304,12124352,2885917,10716706,23204226,11571643","[{'link': 'https://ascopubs.org/doi/full/10.1200/PO.19.00223', 'abstract': 'Mondaca et al. JCO PO, 2019'}]",LEVEL_3B,,,,LEVEL_Fda3,[],[],,"ERBB2, a receptor tyrosine kinase, is altered by mutation, amplification and/or overexpression in various cancer types, most frequently in breast, esophagogastric and endometrial cancers.",ERBB2 amplification is known to be oncogenic.,"While the HER2-targeted antibody trastuzumab is FDA-approved for the treatment of patients with HER2-positive breast and gastric cancers, and the HER2-targeted kinase inhibitor tucatinib in combination with trastuzumab is FDA-approved for patients with HER2-positive colorectal cancer, their clinical utility in patients with HER2-positive high-grade serous ovarian cancer is unknown.",,,[],[],Trastuzumab;Lapatinib;Ado-Trastuzumab Emtansine;Pembrolizumab;Tucatinib;Trastuzumab Deruxtecan;Margetuximab,v4.10,2023-10-16 00:00:00,,M035_pOvaR_DNA5
495713,35,,BCL2,596,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"BCL2, an anti-apoptotic protein, is frequently altered in non-Hodgkin lymphomas.","BCL2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-01-30 00:00:00,,M035_pOvaR_DNA5
495714,35,,TCF3,6929,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in TCF3 is: Truncating mutations in TCF3 can occur throughout the entire gene and are predicted to lead to loss of its activity (PMID: 29625055). TCF3 encodes a member of the E protein family of helix-loop-helix transcription factors, and it has been shown to be involved in lymphocyte, skin and neural development by regulating the Wnt signaling pathway (PMID: 25990863,17018284, 24832538). Chromosomal translocations involving TCF3 have been shown to be associated with the development of several lymphoid malignancies (PMID: 25729575, 27461063, 31575852). Germline truncating mutations in TCF3 have been shown to lead to severe hypogammaglobulinemia and predispose to B-ALL (PMID: 30063982, 28532655). Additionally, somatic truncating mutations in TCF3 have been identified in patients with several types of carcinomas (PMID: 29625055)",Likely Loss-of-function,"24832538,25729575,30063982,29625055,28532655,17018284,25990863,27461063,31575852",[],,,,,,[],[],,"TCF3, a transcription factor involved in lymphopoiesis, is altered by mutation or deletion in various cancer types.","The TCF3 Deletion is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TCF3 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2020-06-14 00:00:00,,M035_pOvaR_DNA5
495715,35,,CEBPA,1050,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"CEBPA, a tumor suppressor and transcription factor, is recurrently altered by mutation in acute myeloid leukemia.","CEBPA amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CEBPA-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2020-06-20 00:00:00,,M035_pOvaR_DNA5
495716,35,,CRLF2,64109,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"CRLF2, a cytokine receptor, is recurrently altered by chromosomal rearrangement in B-cell acute lymphoblastic leukemia.","CRLF2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CRLF2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-02-14 00:00:00,,M035_pOvaR_DNA5
495717,35,,ZRSR2,8233,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in ZRSR2 is: ZRSR2 truncating mutations result in several forms of C-terminally truncated protein. These mutations are found in myelodysplastic syndrome and are predominantly found in male patients given the location of ZRSR2 on the X chromosome (PMID: ). Knockdown of ZRSR2 in HEK293T cells showed aberrant splicing and global intron retention, showing the importance of ZRSR2 in the splicing of U12-type introns. Knockdown of ZRSR2 in human hematopoietic stem cells showed reduced proliferation and colony formation but also showed defects in differentiation. Together this suggests that loss of ZRSR2 may contribute to defective differentiation due to splicing defects (PMID: 25586593).",Likely Loss-of-function,25586593,[],,,,,,[],[],,"ZRSR2, a splicing factor,  is altered in various hematological malignancies.","The ZRSR2 Deletion is a truncating mutationZRSR2, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ZRSR2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-12-10 00:00:00,,M035_pOvaR_DNA5
495718,35,,BRCA1,672,S1383*,,,HGSOC,stop_gained,1383,1383,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in BRCA1 is: Truncating mutations in BRCA1 can lead to varying C-terminally truncated proteins that results in aberrant protein folding, contributing to loss of BRCA1 protein function. Human breast cancer cell lines that contain a truncating mutation in BRCA1 display elevated levels of aneuploidy and impaired DNA damage response. In addition, truncating mutations have been shown to induce aberrant protein localization, which may impact the interaction of important binding partners (PMID: 20608970). Mouse models of BRCA1 truncating mutations develop cancer, including mammary carcinomas, lymphomas and ovarian carcinomas (PMID: 11358863, 12483515, 12947386).",Likely Loss-of-function,"11358863,20608970,12483515,12947386",[],LEVEL_1,,,,LEVEL_Fda2,[],[],,"BRCA1, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.","The BRCA1 S1383* is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.","The PARP inhibitors olaparib, rucaparib and niraparib are FDA-approved for the treatment of patients with ovarian, fallopian tube, and primary peritoneal cancer with deleterious germline or somatic BRCA1 or 2 mutations (olaparib and niraparib are also approved for suspected deleterious mutations in this setting).",,,[],[],Olaparib;Rucaparib;Niraparib;Talazoparib,v4.10,2023-07-05 00:00:00,,M035_ME3522_BC_DNA1
495721,35,,TP53,7157,V197Cfs*12,,,HGSOC,frameshift_variant,196,197,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in TP53 is: Truncating mutations of TP53 occur throughout the gene and lead to the production of several C-terminally truncated protein forms. These alterations are predicted to be inactivating and are associated with poor prognosis (PMID: 11900253, 11753428, 16007150, 21467160, 19336573). Experimental studies have revealed that truncating mutations promote cancer cell proliferation, survival and metastasis, since ectopic expression of these mutations in melanoma cells increased cell motility and tumor formation in vivo. This was due in part to aberrant localization of truncated proteins to the mitochondria, regulating genes involved in cell survival, including CypD (PMID: 27759562).",Likely Loss-of-function,"19336573,27759562,16007150,11753428,11900253,21467160",[],,,,,,[],[],,"TP53, a tumor suppressor in the DNA damage pathway, is the most frequently mutated gene in cancer.","The TP53 V197Cfs*12 is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP53 V197Cfs*12 mutant high-grade serous ovarian cancer.,,,[],[],,v4.10,2017-06-13 00:00:00,,M035_ME3522_BC_DNA1
495724,35,,NOTCH1,4851,N229Afs*29,,,HGSOC,frameshift_variant,229,248,,,,,Oncogenic,"The mutation effect description for Truncating mutations upstream of transactivation domain in NOTCH1 is: NOTCH1 truncating mutations include recurrent nonsense, frameshift or splice-site mutations in NOTCH1 leading to truncation and functional inactivation of the NOTCH1 protein (PMID: 24651013, 22006338). These mutations typically occur upstream of the intracellular transactivation domain (TAD) of NOTCH1, most often in the N-terminal extracellular epidermal growth factor (EGF) repeats (amino acids 1-1444), or less commonly in intracellular domains (amino acids 1735-2250). A variety of solid tumors, most commonly squamous cell carcinomas from various sites, exhibit these mutations (PMID: 21798897, 21798893); however additional studies are required to fully understand the functional consequences of these mutations.",Likely Loss-of-function,"22006338,21798897,24651013,21798893",[],,,,,,[],[],,"NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor.",The NOTCH1 N229Afs*29 mutation is known to be oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NOTCH1 N229Afs*29 mutant high-grade serous ovarian cancer.,,,[],[],,v4.10,2017-04-13 00:00:00,,M035_ME3522_BC_DNA1
495727,503,,TNFRSF14,8764,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in TNFRSF14 is: Truncating mutations in TNFRSF14 can occur throughout the entire gene and are predicted to lead to loss of its activity (PMID: 27257180, 29625055). TNFRSF14 encodes a Tumor Necrosis Factor (TNF) receptor superfamily member that has been shown to be involved in signal transduction pathways that regulate inflammatory and T-cell immune responses (PMID: 27982078, 21402741, 11742858). This gene has also been known for its role in mediating herpes virus entry into cells (PMID: 22017438, 24307582). TNFRSF14 aberrations have been associated with worse prognosis in follicular lymphoma, and they also seem to increase the susceptibility to allogeneic T-cells received during bone marrow transplantation (PMID:20884631, 27103745). Reduced expression of this protein has been reported in follicular (PMID: 27257180), marginal zone (PMID: 27297871) and Hodgkin (PMID: 26650888) lymphomas, and this gene has also been shown to act as a tumor suppressor in bladder carcinomas by promoting apoptosis (PMID: 30066919). Additionally, truncating mutations in TNFRSF14 have been identified in exome-sequencing studies in other malignancies (PMID: 29625055)",Likely Loss-of-function,"27982078,27103745,27257180,24307582,29625055,22017438,27297871,26650888,21402741,20884631,30066919,11742858",[],,,,,,[],[],,"TNFRSF14, a cell surface receptor in the tumor necrosis factor family, is recurrently altered by mutation and deletion in hematologic malignancies.","The TNFRSF14 Deletion is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TNFRSF14 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2020-06-14 00:00:00,,D351_iAdnL1_DNA1
495728,503,,BARD1,580,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,Deletions of BARD1 are found in patients with breast cancer and are thought to serve as an alternative breast cancer susceptibility gene to BRCA1 (PMID: 20842729). In vitro studies using Bard1-null mouse mammary carcinoma cell lines show that BARD1 is required for maintenance of chromosomal stability and homologous recombination of DNA double-strand breaks (PMID: 17848578). BARD1 null mice develop breast cancer (PMID: 20029420).,Likely Loss-of-function,"20029420,17848578,20842729",[],LEVEL_3B,,,,LEVEL_Fda3,[],[],,"BARD1, a tumor suppressor involved in the DNA damage response, is altered by mutation in breast and ovarian cancers.",BARD1 deletion is likely oncogenic.,"While the PARP inhibitor olaparib is FDA-approved for the treatment of patients with metastatic castration-resistant prostate cancer with deleterious or suspected deleterious germline or somatic BARD1 mutations, its clinical utility in patients with BARD1 deletion high-grade serous ovarian cancer is unknown.",,,[],[],Olaparib,v4.10,2023-03-03 00:00:00,,D351_iAdnL1_DNA1
495729,503,,PIK3CA,5290,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"PIK3CA amplification is an infrequent event across cancers (PMID: 28481359), although several individual studies have reported them in lung squamous cell carcinoma, ovarian, esophagus, cervical, and head and neck tumors (PMID: 22960745, 21720365, 25631445, 23636398). PIK3CA gene amplification has been correlated with PIK3CA protein overexpression (PMID: 17992665,19697359). PIK3CA overexpression enhances growth and migration (PMID: 17803655, 26876212). PIK3CA amplifications associate with poor prognosis in several cancers (PMID: 22994622, 22292935, 27095573). Some studies have found a correlation between PIK3CA copy number amplification and sensitivity to PI3K inhibitors (PMID: 24608574, 23136191). Amplification of PIK3CA known pathogenic mutant alleles have also been reported (PMID: 19706770). Expression of this mutation in a patient-derived xenograft model of lung squamous cell carcinoma demonstrated that it was not sensitive to the pan-PIK3CA inhibitor BKM120 similar to PDX models expressing wildtype PIK3CA (PMID: 30093452).",Likely Gain-of-function,"21720365,22960745,17992665,23136191,30093452,19706770,28481359,22292935,22994622,19697359,25631445,24608574,26876212,23636398,27095573,17803655",[],,,,,,[],[],,"PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers.",PIK3CA amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CA-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-04-18 00:00:00,,D351_iAdnL1_DNA1
495730,503,,BCL6,604,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"The amplification of BCL6 has been observed across a range of tumor types. Specifically, in follicular lymphoma BCL6 amplification was observed in a cohort of tumors lacking otherwise typical IGH/BCL2 rearrangements (PMID: 18500267, 24887414). BCL6 is a transcriptional regulator in germinal centers, from which human lymphomas often derive. In model systems, overexpression of BCL6 results in an anti-apoptotic and chemotherapy resistant phenotype (PMID: 15577913, 16142238).",Likely Gain-of-function,"16142238,18500267,24887414,15577913",[],,,,,,[],[],,"BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas.",BCL6 amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,D351_iAdnL1_DNA1
495731,503,,TP63,8626,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"TP63, a transcription factor, is recurrently altered by chromosomal rearrangement in hematologic malignancies.","TP63 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP63-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,D351_iAdnL1_DNA1
495732,503,,ESR1,2099,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers.,"ESR1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-07-23 00:00:00,,D351_iAdnL1_DNA1
495733,503,,PTCH1,5727,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"PTCH1, a tumor suppressor and inhibitor of the hedgehog pathway, is recurrently mutated in basal cell carcinoma.","There is no available functional data about the PTCH1 deletion (last reviewed on 02/24/2017), and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PTCH1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2017-03-22 00:00:00,,D351_iAdnL1_DNA1
495734,503,,MAF,4094,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"MAF, a transcription factor, is recurrently altered by rearrangement in multiple myeloma.","MAF deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAF deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-30 00:00:00,,D351_iAdnL1_DNA1
495735,503,,FANCA,2175,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"FANCA deletion results in loss of the FANCA protein. These mutations are found in Fanconi anemia (PMID: 12827451). FANCA deletions in acute myeloid leukemia samples resulted in reduced protein expression compared to control samples (PMID: 14749703). In vitro studies demonstrated that loss of FANCA results in sensitization of Fanconi anemia fibroblast cells to DNA cross-linking agents such as mitomycin C when as measured by decreased cell proliferation upon drug treatment (PMID: 11739169, 12637330).",Likely Loss-of-function,"12637330,11739169,12827451,14749703",[],LEVEL_3B,,,,LEVEL_Fda3,[],[],,FANCA is a tumor suppressor and DNA repair protein. Germline mutations of FANCA are associated with the cancer predisposition syndrome Fanconi Anemia.,FANCA deletion is likely oncogenic.,"While the PARP inhibitor talazoparib in combination with enzalutamide is FDA-approved for the treatment of patients with FANCA-mutant metastatic castration-resistant prostate cancer, the clinical utility of these agents in patients with FANCA deletion high-grade serous ovarian cancer is unknown.",,,[],[],Talazoparib,v4.10,2023-07-11 00:00:00,,D351_iAdnL1_DNA1
495736,503,,KLF2,10365,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"KLF2, a transcription factor that regulates the activity of NF-κB, is recurrently altered by mutation in splenic marginal zone lymphoma.","KLF2 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KLF2-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-20 00:00:00,,D351_iAdnL1_DNA1
495737,503,,TNFRSF14,8764,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in TNFRSF14 is: Truncating mutations in TNFRSF14 can occur throughout the entire gene and are predicted to lead to loss of its activity (PMID: 27257180, 29625055). TNFRSF14 encodes a Tumor Necrosis Factor (TNF) receptor superfamily member that has been shown to be involved in signal transduction pathways that regulate inflammatory and T-cell immune responses (PMID: 27982078, 21402741, 11742858). This gene has also been known for its role in mediating herpes virus entry into cells (PMID: 22017438, 24307582). TNFRSF14 aberrations have been associated with worse prognosis in follicular lymphoma, and they also seem to increase the susceptibility to allogeneic T-cells received during bone marrow transplantation (PMID:20884631, 27103745). Reduced expression of this protein has been reported in follicular (PMID: 27257180), marginal zone (PMID: 27297871) and Hodgkin (PMID: 26650888) lymphomas, and this gene has also been shown to act as a tumor suppressor in bladder carcinomas by promoting apoptosis (PMID: 30066919). Additionally, truncating mutations in TNFRSF14 have been identified in exome-sequencing studies in other malignancies (PMID: 29625055)",Likely Loss-of-function,"27982078,27103745,27257180,24307582,29625055,22017438,27297871,26650888,21402741,20884631,30066919,11742858",[],,,,,,[],[],,"TNFRSF14, a cell surface receptor in the tumor necrosis factor family, is recurrently altered by mutation and deletion in hematologic malignancies.","The TNFRSF14 Deletion is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TNFRSF14 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2020-06-14 00:00:00,,D351_iOme1_DNA1
495738,503,,PIK3CA,5290,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"PIK3CA amplification is an infrequent event across cancers (PMID: 28481359), although several individual studies have reported them in lung squamous cell carcinoma, ovarian, esophagus, cervical, and head and neck tumors (PMID: 22960745, 21720365, 25631445, 23636398). PIK3CA gene amplification has been correlated with PIK3CA protein overexpression (PMID: 17992665,19697359). PIK3CA overexpression enhances growth and migration (PMID: 17803655, 26876212). PIK3CA amplifications associate with poor prognosis in several cancers (PMID: 22994622, 22292935, 27095573). Some studies have found a correlation between PIK3CA copy number amplification and sensitivity to PI3K inhibitors (PMID: 24608574, 23136191). Amplification of PIK3CA known pathogenic mutant alleles have also been reported (PMID: 19706770). Expression of this mutation in a patient-derived xenograft model of lung squamous cell carcinoma demonstrated that it was not sensitive to the pan-PIK3CA inhibitor BKM120 similar to PDX models expressing wildtype PIK3CA (PMID: 30093452).",Likely Gain-of-function,"21720365,22960745,17992665,23136191,30093452,19706770,28481359,22292935,22994622,19697359,25631445,24608574,26876212,23636398,27095573,17803655",[],,,,,,[],[],,"PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers.",PIK3CA amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CA-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-04-18 00:00:00,,D351_iOme1_DNA1
495739,503,,BCL6,604,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"The amplification of BCL6 has been observed across a range of tumor types. Specifically, in follicular lymphoma BCL6 amplification was observed in a cohort of tumors lacking otherwise typical IGH/BCL2 rearrangements (PMID: 18500267, 24887414). BCL6 is a transcriptional regulator in germinal centers, from which human lymphomas often derive. In model systems, overexpression of BCL6 results in an anti-apoptotic and chemotherapy resistant phenotype (PMID: 15577913, 16142238).",Likely Gain-of-function,"16142238,18500267,24887414,15577913",[],,,,,,[],[],,"BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas.",BCL6 amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,D351_iOme1_DNA1
495740,503,,TP63,8626,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"TP63, a transcription factor, is recurrently altered by chromosomal rearrangement in hematologic malignancies.","TP63 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP63-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,D351_iOme1_DNA1
495741,503,,ESR1,2099,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers.,"ESR1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-07-23 00:00:00,,D351_iOme1_DNA1
495742,503,,MAF,4094,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"MAF, a transcription factor, is recurrently altered by rearrangement in multiple myeloma.","MAF deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAF deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-30 00:00:00,,D351_iOme1_DNA1
495743,503,,MALT1,10892,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"MALT1, a paracaspase, is recurrently altered by chromosomal rearrangement in MALT lymphoma.","MALT1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MALT1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-22 00:00:00,,D351_iOme1_DNA1
495744,503,,BCL2,596,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"BCL2, an anti-apoptotic protein, is frequently altered in non-Hodgkin lymphomas.","BCL2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-01-30 00:00:00,,D351_iOme1_DNA1
495745,503,,KLF2,10365,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"KLF2, a transcription factor that regulates the activity of NF-κB, is recurrently altered by mutation in splenic marginal zone lymphoma.","KLF2 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KLF2-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-20 00:00:00,,D351_iOme1_DNA1
495746,503,,TNFRSF14,8764,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in TNFRSF14 is: Truncating mutations in TNFRSF14 can occur throughout the entire gene and are predicted to lead to loss of its activity (PMID: 27257180, 29625055). TNFRSF14 encodes a Tumor Necrosis Factor (TNF) receptor superfamily member that has been shown to be involved in signal transduction pathways that regulate inflammatory and T-cell immune responses (PMID: 27982078, 21402741, 11742858). This gene has also been known for its role in mediating herpes virus entry into cells (PMID: 22017438, 24307582). TNFRSF14 aberrations have been associated with worse prognosis in follicular lymphoma, and they also seem to increase the susceptibility to allogeneic T-cells received during bone marrow transplantation (PMID:20884631, 27103745). Reduced expression of this protein has been reported in follicular (PMID: 27257180), marginal zone (PMID: 27297871) and Hodgkin (PMID: 26650888) lymphomas, and this gene has also been shown to act as a tumor suppressor in bladder carcinomas by promoting apoptosis (PMID: 30066919). Additionally, truncating mutations in TNFRSF14 have been identified in exome-sequencing studies in other malignancies (PMID: 29625055)",Likely Loss-of-function,"27982078,27103745,27257180,24307582,29625055,22017438,27297871,26650888,21402741,20884631,30066919,11742858",[],,,,,,[],[],,"TNFRSF14, a cell surface receptor in the tumor necrosis factor family, is recurrently altered by mutation and deletion in hematologic malignancies.","The TNFRSF14 Deletion is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TNFRSF14 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2020-06-14 00:00:00,,D351_p2Ome1_DNA1
495747,503,,PIK3CA,5290,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"PIK3CA amplification is an infrequent event across cancers (PMID: 28481359), although several individual studies have reported them in lung squamous cell carcinoma, ovarian, esophagus, cervical, and head and neck tumors (PMID: 22960745, 21720365, 25631445, 23636398). PIK3CA gene amplification has been correlated with PIK3CA protein overexpression (PMID: 17992665,19697359). PIK3CA overexpression enhances growth and migration (PMID: 17803655, 26876212). PIK3CA amplifications associate with poor prognosis in several cancers (PMID: 22994622, 22292935, 27095573). Some studies have found a correlation between PIK3CA copy number amplification and sensitivity to PI3K inhibitors (PMID: 24608574, 23136191). Amplification of PIK3CA known pathogenic mutant alleles have also been reported (PMID: 19706770). Expression of this mutation in a patient-derived xenograft model of lung squamous cell carcinoma demonstrated that it was not sensitive to the pan-PIK3CA inhibitor BKM120 similar to PDX models expressing wildtype PIK3CA (PMID: 30093452).",Likely Gain-of-function,"21720365,22960745,17992665,23136191,30093452,19706770,28481359,22292935,22994622,19697359,25631445,24608574,26876212,23636398,27095573,17803655",[],,,,,,[],[],,"PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers.",PIK3CA amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CA-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-04-18 00:00:00,,D351_p2Ome1_DNA1
495748,503,,BCL6,604,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"The amplification of BCL6 has been observed across a range of tumor types. Specifically, in follicular lymphoma BCL6 amplification was observed in a cohort of tumors lacking otherwise typical IGH/BCL2 rearrangements (PMID: 18500267, 24887414). BCL6 is a transcriptional regulator in germinal centers, from which human lymphomas often derive. In model systems, overexpression of BCL6 results in an anti-apoptotic and chemotherapy resistant phenotype (PMID: 15577913, 16142238).",Likely Gain-of-function,"16142238,18500267,24887414,15577913",[],,,,,,[],[],,"BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas.",BCL6 amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,D351_p2Ome1_DNA1
495749,503,,TP63,8626,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"TP63, a transcription factor, is recurrently altered by chromosomal rearrangement in hematologic malignancies.","TP63 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP63-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,D351_p2Ome1_DNA1
495750,503,,ESR1,2099,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers.,"ESR1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-07-23 00:00:00,,D351_p2Ome1_DNA1
495751,503,,JAK2,3717,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematologic malignancies.","JAK2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2021-10-05 00:00:00,,D351_p2Ome1_DNA1
495752,503,,MAF,4094,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"MAF, a transcription factor, is recurrently altered by rearrangement in multiple myeloma.","MAF deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAF deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-30 00:00:00,,D351_p2Ome1_DNA1
495753,503,,MALT1,10892,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"MALT1, a paracaspase, is recurrently altered by chromosomal rearrangement in MALT lymphoma.","MALT1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MALT1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-22 00:00:00,,D351_p2Ome1_DNA1
495754,503,,BCL2,596,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"BCL2, an anti-apoptotic protein, is frequently altered in non-Hodgkin lymphomas.","BCL2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-01-30 00:00:00,,D351_p2Ome1_DNA1
495755,503,,TYK2,7297,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"TYK2, a non-receptor kinase, is infrequently altered by mutation and rearrangement in hematopoietic malignancies.","TYK2 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TYK2-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-08-23 00:00:00,,D351_p2Ome1_DNA1
495756,503,,EPOR,2057,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"EPOR, a cytokine receptor, is recurrently altered by chromosomal rearrangement in familial erythrocytosis and acute lymphoblastic leukemia.","EPOR amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EPOR-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-17 00:00:00,,D351_p2Ome1_DNA1
495757,503,,CALR,811,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"CALR, a calcium-binding protein, is altered in various solid and hematologic malignancies including myeloproliferative neoplasms.","CALR amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CALR-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-10-04 00:00:00,,D351_p2Ome1_DNA1
495758,503,,KLF2,10365,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"KLF2, a transcription factor that regulates the activity of NF-κB, is recurrently altered by mutation in splenic marginal zone lymphoma.","KLF2 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KLF2-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-20 00:00:00,,D351_p2Ome1_DNA1
495759,503,,DNMT3A,1788,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"DNMT3A, a tumor suppressor and DNA methyltransferase, is recurrently mutated in acute myeloid leukemia and other hematologic malignancies.","DNMT3A amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DNMT3A-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-10-04 00:00:00,,D351_p2Per1_DNA1
495760,503,,ALK,238,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"ALK amplification results in overexpression of the protein. This mutation has been found in various types of cancers (PMID: 22614325, 21474455). Overexpression of ALK in neuroblastoma cell lines demonstrated that it is activating as measured by increased cell proliferation, colony formation, and cell invasiveness (PMID: 24356251).",Likely Gain-of-function,"21474455,24356251,22614325",[],,,,,,[],[],,"ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancer types including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumors.",ALK amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ALK-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2020-04-23 00:00:00,,D351_p2Per1_DNA1
495761,503,,SF3B1,23451,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies.","SF3B1 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with SF3B1-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-10-22 00:00:00,,D351_p2Per1_DNA1
495762,503,,IDH1,3417,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"IDH1, a cell metabolism enzyme, is recurrently mutated in various cancer types including acute myeloid leukemia and gliomas.","IDH1 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IDH1-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-04 00:00:00,,D351_p2Per1_DNA1
495763,503,,PIK3CA,5290,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"PIK3CA amplification is an infrequent event across cancers (PMID: 28481359), although several individual studies have reported them in lung squamous cell carcinoma, ovarian, esophagus, cervical, and head and neck tumors (PMID: 22960745, 21720365, 25631445, 23636398). PIK3CA gene amplification has been correlated with PIK3CA protein overexpression (PMID: 17992665,19697359). PIK3CA overexpression enhances growth and migration (PMID: 17803655, 26876212). PIK3CA amplifications associate with poor prognosis in several cancers (PMID: 22994622, 22292935, 27095573). Some studies have found a correlation between PIK3CA copy number amplification and sensitivity to PI3K inhibitors (PMID: 24608574, 23136191). Amplification of PIK3CA known pathogenic mutant alleles have also been reported (PMID: 19706770). Expression of this mutation in a patient-derived xenograft model of lung squamous cell carcinoma demonstrated that it was not sensitive to the pan-PIK3CA inhibitor BKM120 similar to PDX models expressing wildtype PIK3CA (PMID: 30093452).",Likely Gain-of-function,"21720365,22960745,17992665,23136191,30093452,19706770,28481359,22292935,22994622,19697359,25631445,24608574,26876212,23636398,27095573,17803655",[],,,,,,[],[],,"PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers.",PIK3CA amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CA-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-04-18 00:00:00,,D351_p2Per1_DNA1
495764,503,,BCL6,604,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"The amplification of BCL6 has been observed across a range of tumor types. Specifically, in follicular lymphoma BCL6 amplification was observed in a cohort of tumors lacking otherwise typical IGH/BCL2 rearrangements (PMID: 18500267, 24887414). BCL6 is a transcriptional regulator in germinal centers, from which human lymphomas often derive. In model systems, overexpression of BCL6 results in an anti-apoptotic and chemotherapy resistant phenotype (PMID: 15577913, 16142238).",Likely Gain-of-function,"16142238,18500267,24887414,15577913",[],,,,,,[],[],,"BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas.",BCL6 amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,D351_p2Per1_DNA1
495765,503,,TP63,8626,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"TP63, a transcription factor, is recurrently altered by chromosomal rearrangement in hematologic malignancies.","TP63 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP63-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,D351_p2Per1_DNA1
495766,503,,DUSP22,56940,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in DUSP22 is: Truncating mutations in DUSP22 generally occur in exon 1 of the gene and typically result in loss of the protein. These mutations have been identified in patients with cutaneous and peripheral anaplastic large T-cell lymphomas, specifically ALK-negative ALCL tumors that harbor chromosome 6p25 deletions or rearrangements (PMID: 27626696). In vitro studies with DUSP22-deficient malignant T cells demonstrate that loss of DUSP22 is inactivating as measured by inhibition of cellular expansion, soft agar clonogenicity and tumorigenicity, and upregulation of apoptosis following re-expression of DUSP22 (PMID: 27626696).",Likely Loss-of-function,27626696,[],,,,,,[],[],,"DUSP22, a protein phosphatase, is recurrently altered by chromosomal rearrangement in anaplastic large cell lymphoma.","The DUSP22 Deletion is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with DUSP22 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2023-01-27 00:00:00,,D351_p2Per1_DNA1
495767,503,,IRF4,3662,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"IRF4, a transcription factor, is altered by mutation and chromosomal rearrangement in various hematologic malignancies.","IRF4 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IRF4 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-17 00:00:00,,D351_p2Per1_DNA1
495768,503,,ESR1,2099,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers.,"ESR1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-07-23 00:00:00,,D351_p2Per1_DNA1
495769,503,,NRG1,3084,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"NRG1, a ligand that binds HER3, is recurrently altered by fusions in lung, pancreatic, and other cancers.","NRG1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NRG1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2022-07-15 00:00:00,,D351_p2Per1_DNA1
495770,503,,FGFR1,2260,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"FGFR1, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancer types including lung and breast cancers.","FGFR1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-07-23 00:00:00,,D351_p2Per1_DNA1
495771,503,,JAK2,3717,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematologic malignancies.","JAK2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2021-10-05 00:00:00,,D351_p2Per1_DNA1
495772,503,,CD274,29126,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"CD274 (also known as PD-L1) is an immune receptor ligand. Expression of PD-L1 may help predict response to immunotherapies targeted against PD-L1 and its receptor, PD-1.","CD274 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CD274 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-03-07 00:00:00,,D351_p2Per1_DNA1
495773,503,,PDCD1LG2,80380,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"PDCD1LG2, a ligand of T-cell receptors involved in immune suppression, is overexpressed in various cancer types.","PDCD1LG2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PDCD1LG2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-16 00:00:00,,D351_p2Per1_DNA1
495774,503,,GATA3,2625,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"GATA3 deletions have been detected in patients with breast cancer and commonly results in the production of truncated protein forms (PMID: 15361840). Experimental studies suggest that these mutations alter the cellular localization of the protein (PMID: 15361840), and affects DNA-binding and transactivation abilities (PMID: 7829479, 10935639, 24758297, 26637396) leading to increased cellular invasiveness.",Likely Loss-of-function,"10935639,15361840,26637396,24758297,7829479",[],,,,,,[],[],,"GATA3, a transcription factor, is altered by mutation or amplification in various cancers, most frequently in breast cancer.",GATA3 deletion is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GATA3 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-06-01 00:00:00,,D351_p2Per1_DNA1
495775,503,,BIRC3,330,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"Deletion of a region of 11q that encodes BIRC3 is found in chronic lymphocytic leukemia (CLL) and is associated with increased disease progression (PMID: 30487125). CLL cell lines engineered to have BIRC3 deletions show that the absence of BIRC3 is associated with activation of the NFkB pathway, increased expression of anti-apoptotic BCL-2 family members and increased sensitivity to NF-kB inhibition compared to cells expressing wildtype BIRC3 (PMID: 30487125).",Likely Loss-of-function,30487125,[],,,,,,[],[],,"BIRC3, an anti-apoptotic protein, is altered in various cancer types.",BIRC3 deletion is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BIRC3 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-10-01 00:00:00,,D351_p2Per1_DNA1
495776,503,,ATM,472,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"ATM deletions result in the loss of the protein. These mutations have been found in chronic lymphocytic leukemia. Expression of ATM deletions in patients led to the deregulation of apoptotic and DNA repair genes, significantly shorter survival and chemoresistance (PMID: 21993670, 16014569).",Likely Loss-of-function,"21993670,16014569",[],LEVEL_3B,,,,LEVEL_Fda3,[],[],,"ATM, a kinase involved in DNA damage response, is inactivated in various solid and hematologic malignancies. Germline ATM mutations are a defining feature of ataxia telangiectasia syndrome, a neurodegenerative, autosomal disorder that predisposes to various cancers.",ATM deletion is likely oncogenic.,"While the PARP inhibitors olaparib as a single agent and talazoparib in combination with enzalutamide are FDA-approved for the treatment of patients with metastatic castration-resistant prostate cancer with ATM mutations, the clinical utility of these agents in patients with ATM deletion high-grade serous ovarian cancer is unknown.",,,[],[],Olaparib;Talazoparib,v4.10,2023-07-11 00:00:00,,D351_p2Per1_DNA1
495777,503,,ETV6,2120,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"ETV6, a transcription factor, is frequently altered by chromosomal rearrangement in hematologic malignancies.","ETV6 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ETV6-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,D351_p2Per1_DNA1
495778,503,,KRAS,3845,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"KRAS amplification results in overexpression of the protein. This mutation has been found in germ cell tumors and esophagogastric and ovarian cancer (cBioPortal, Zehir, A et al. Nature Medicine, 2017). In vitro studies have demonstrated that this mutation confers resistance to the tyrosine kinase inhibitor crizotinib, EGFR inhibitors cetuximab or panitumumab, MET inhibitors PHA-665752 or JNJ38877605 and MEK inhibitors AZD6244 or GSK1120212 in patient-derived lung cancer cell line and xenograft models, colorectal cancer cell line models, MET-amplified cell line models and gastric cancer cell line models (PMID: 29808010, 30072474, 23404247, 20841479). Analyses of 475 patients with endometrial cancer demonstrated that KRAS amplification is associated with metastasis (PMID: 23099803).",Likely Gain-of-function,"23099803,29808010,30072474,20841479,23404247",[],,,,,,[],[],,"KRAS, a GTPase which functions as an upstream regulator of the MAPK pathway, is frequently mutated in various cancer types including lung, colorectal and pancreatic cancers.",KRAS amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KRAS-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2021-11-18 00:00:00,,D351_p2Per1_DNA1
495779,503,,KLF2,10365,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"KLF2, a transcription factor that regulates the activity of NF-κB, is recurrently altered by mutation in splenic marginal zone lymphoma.","KLF2 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KLF2-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-20 00:00:00,,D351_p2Per1_DNA1
495780,503,,ASXL1,171023,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"ASXL1, a tumor suppressor and epigenetic regulator, is inactivated by mutation in various cancer types, most frequently in myeloid malignancies.","ASXL1 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ASXL1-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-02-22 00:00:00,,D351_p2Per1_DNA1
495781,503,,EP300,2033,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"EP300 truncating mutations result in EP300 proteins that lack some or all of the key enzymatic domains: the histone acetyltransferase (HAT) domain, the bromodomain and transcription factor binding domains (PMID: 12402157). Functional studies have shown that deletion of these domains result in decreased acetyltransferase and tumor suppressive activity (PMID: 12237408). Deletion of one EP300 allele is highly associated with loss of the second EP300 allele (PMID: 10700188) and can lead to disruption of signaling cascades such as the TGFβ pathway (PMID: 12237408).",Likely Loss-of-function,"12237408,10700188,12402157",[],,,,,,[],[],,"EP300, a tumor suppressor and histone acetyltransferase, is inactivated in various cancer types.",EP300 deletion is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EP300 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-02-14 00:00:00,,D351_p2Per1_DNA1
495782,503,,CRLF2,64109,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"CRLF2, a cytokine receptor, is recurrently altered by chromosomal rearrangement in B-cell acute lymphoblastic leukemia.","CRLF2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CRLF2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-02-14 00:00:00,,D351_p2Per1_DNA1
495783,503,,ZRSR2,8233,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in ZRSR2 is: ZRSR2 truncating mutations result in several forms of C-terminally truncated protein. These mutations are found in myelodysplastic syndrome and are predominantly found in male patients given the location of ZRSR2 on the X chromosome (PMID: ). Knockdown of ZRSR2 in HEK293T cells showed aberrant splicing and global intron retention, showing the importance of ZRSR2 in the splicing of U12-type introns. Knockdown of ZRSR2 in human hematopoietic stem cells showed reduced proliferation and colony formation but also showed defects in differentiation. Together this suggests that loss of ZRSR2 may contribute to defective differentiation due to splicing defects (PMID: 25586593).",Likely Loss-of-function,25586593,[],,,,,,[],[],,"ZRSR2, a splicing factor,  is altered in various hematological malignancies.","The ZRSR2 Deletion is a truncating mutationZRSR2, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ZRSR2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-12-10 00:00:00,,D351_p2Per1_DNA1
495784,503,,BCOR,54880,Deletion,,,HGSOC,,,,,,,,Oncogenic,"BCOR deletions in patients with acute myeloid leukemia are associated with inferior outcome (PMID: 2212066). Experimental studies using AML patient samples suggest that loss of BCOR protein is associated with increased cell proliferation and myeloid differentiation (PMID: 26847029, 28827447). Knockout of BCOR in Myc-hematopoietic progenitor cells using CRISPR/Cas9 led to increased lymphomagenesis compared to Myc-induced lymphomagenesis alone when transplanted into irradiated mice (PMID: 28262675).",Loss-of-function,"26847029,28827447,2212066,28262675",[],,,,,,[],[],,"BCOR, a transcriptional repressor, is altered in various solid and hematologic malignancies including acute myeloid leukemia.",BCOR deletion is known to be oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCOR deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-09-13 00:00:00,,D351_p2Per1_DNA1
495785,503,,TNFRSF14,8764,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in TNFRSF14 is: Truncating mutations in TNFRSF14 can occur throughout the entire gene and are predicted to lead to loss of its activity (PMID: 27257180, 29625055). TNFRSF14 encodes a Tumor Necrosis Factor (TNF) receptor superfamily member that has been shown to be involved in signal transduction pathways that regulate inflammatory and T-cell immune responses (PMID: 27982078, 21402741, 11742858). This gene has also been known for its role in mediating herpes virus entry into cells (PMID: 22017438, 24307582). TNFRSF14 aberrations have been associated with worse prognosis in follicular lymphoma, and they also seem to increase the susceptibility to allogeneic T-cells received during bone marrow transplantation (PMID:20884631, 27103745). Reduced expression of this protein has been reported in follicular (PMID: 27257180), marginal zone (PMID: 27297871) and Hodgkin (PMID: 26650888) lymphomas, and this gene has also been shown to act as a tumor suppressor in bladder carcinomas by promoting apoptosis (PMID: 30066919). Additionally, truncating mutations in TNFRSF14 have been identified in exome-sequencing studies in other malignancies (PMID: 29625055)",Likely Loss-of-function,"27982078,27103745,27257180,24307582,29625055,22017438,27297871,26650888,21402741,20884631,30066919,11742858",[],,,,,,[],[],,"TNFRSF14, a cell surface receptor in the tumor necrosis factor family, is recurrently altered by mutation and deletion in hematologic malignancies.","The TNFRSF14 Deletion is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TNFRSF14 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2020-06-14 00:00:00,,D351_pOme1_DNA1
495786,503,,PIK3CA,5290,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"PIK3CA amplification is an infrequent event across cancers (PMID: 28481359), although several individual studies have reported them in lung squamous cell carcinoma, ovarian, esophagus, cervical, and head and neck tumors (PMID: 22960745, 21720365, 25631445, 23636398). PIK3CA gene amplification has been correlated with PIK3CA protein overexpression (PMID: 17992665,19697359). PIK3CA overexpression enhances growth and migration (PMID: 17803655, 26876212). PIK3CA amplifications associate with poor prognosis in several cancers (PMID: 22994622, 22292935, 27095573). Some studies have found a correlation between PIK3CA copy number amplification and sensitivity to PI3K inhibitors (PMID: 24608574, 23136191). Amplification of PIK3CA known pathogenic mutant alleles have also been reported (PMID: 19706770). Expression of this mutation in a patient-derived xenograft model of lung squamous cell carcinoma demonstrated that it was not sensitive to the pan-PIK3CA inhibitor BKM120 similar to PDX models expressing wildtype PIK3CA (PMID: 30093452).",Likely Gain-of-function,"21720365,22960745,17992665,23136191,30093452,19706770,28481359,22292935,22994622,19697359,25631445,24608574,26876212,23636398,27095573,17803655",[],,,,,,[],[],,"PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers.",PIK3CA amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CA-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-04-18 00:00:00,,D351_pOme1_DNA1
495787,503,,BCL6,604,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"The amplification of BCL6 has been observed across a range of tumor types. Specifically, in follicular lymphoma BCL6 amplification was observed in a cohort of tumors lacking otherwise typical IGH/BCL2 rearrangements (PMID: 18500267, 24887414). BCL6 is a transcriptional regulator in germinal centers, from which human lymphomas often derive. In model systems, overexpression of BCL6 results in an anti-apoptotic and chemotherapy resistant phenotype (PMID: 15577913, 16142238).",Likely Gain-of-function,"16142238,18500267,24887414,15577913",[],,,,,,[],[],,"BCL6, a transcriptional repressor involved in immune cell development, is frequently altered by chromosomal rearrangement in lymphomas.",BCL6 amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL6-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,D351_pOme1_DNA1
495788,503,,TP63,8626,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"TP63, a transcription factor, is recurrently altered by chromosomal rearrangement in hematologic malignancies.","TP63 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP63-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-06 00:00:00,,D351_pOme1_DNA1
495789,503,,ESR1,2099,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,ESR1 (estrogen receptor alpha) is a transcription factor that is frequently mutated in hormone-resistant metastatic breast cancers.,"ESR1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ESR1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-07-23 00:00:00,,D351_pOme1_DNA1
495790,503,,JAK2,3717,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematologic malignancies.","JAK2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2021-10-05 00:00:00,,D351_pOme1_DNA1
495791,503,,MAF,4094,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"MAF, a transcription factor, is recurrently altered by rearrangement in multiple myeloma.","MAF deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAF deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-30 00:00:00,,D351_pOme1_DNA1
495792,503,,MALT1,10892,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"MALT1, a paracaspase, is recurrently altered by chromosomal rearrangement in MALT lymphoma.","MALT1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MALT1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-01-22 00:00:00,,D351_pOme1_DNA1
495793,503,,BCL2,596,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"BCL2, an anti-apoptotic protein, is frequently altered in non-Hodgkin lymphomas.","BCL2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-01-30 00:00:00,,D351_pOme1_DNA1
495794,503,,KLF2,10365,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"KLF2, a transcription factor that regulates the activity of NF-κB, is recurrently altered by mutation in splenic marginal zone lymphoma.","KLF2 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KLF2-amplified high-grade serous ovarian cancer.,,,[],[],,v4.10,2019-02-20 00:00:00,,D351_pOme1_DNA1
495795,503,,ATRX,546,R1425Gfs*65,,,HGSOC,frameshift_variant,1423,1423,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in ATRX is: Truncating mutations in ATRX occur throughout several protein domains and leads to reduced protein expression and is associated with DNA methylation. Truncated ATRX variants in both alpha thalassaemia mental retardation (ATR-X) syndrome and alpha thalassemia myelodysplastic syndrome (ATMDS) are most commonly detected in the highly conserved helicase domain and also the P-box and Q-box domains, potential protein-interaction domains (PMID: 8968741, 14592816, 18409179, 17609377). In some cases, the truncated ATRX phenotype can be rescued by expression of a downstream start site through intraexonic skipping of the mutant allele, consistent with a hypomorphic effect (PMID: 18409179, 15591283). Based on loss of function studies, ATRX deletions are expected to result in chromosomal instability and alternate lengthening of telomeres (ALT) (PMID: 21719641, 24148618).",Likely Loss-of-function,"21719641,8968741,24148618,15591283,14592816,18409179,17609377",[],,,,,,[],[],,"ATRX, a tumor suppressor involved in transcriptional regulation, is infrequently altered in cancer.","The ATRX R1425Gfs*65 is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ATRX R1425Gfs*65 mutant high-grade serous ovarian cancer.,,,[],[],,v4.10,2018-10-03 00:00:00,,D351_BDNA13550
495803,503,,TP53,7157,G108_R110del,,,HGSOC,inframe_deletion,107,110,,,,,Likely Oncogenic,"The mutation effect description for DNA binding domain deletions in TP53 is: The DNA-binding domain (DBD) of TP53 allows for contact with target DNA sequences to transactivate downstream genes. Mutations in the DBD result in conformational changes of the protein, altering contact of TP53 with its target DNA sequences and thereby altering transcriptional function (PMID: 8023157, 11900253). Given that TP53 directs the transcription of proteins that enable apoptosis, the inactivation of TP53 results in cells harboring damaged DNA and overall genomic instability (PMID: 11900253, 11900253).",Likely Loss-of-function,"8023157,11900253",[],,,,,,[],[],,"TP53, a tumor suppressor in the DNA damage pathway, is the most frequently mutated gene in cancer.",The TP53 G108_R110del alteration is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TP53 G108_R110del altered high-grade serous ovarian cancer.,,,[],[],,v4.10,2023-03-24 00:00:00,,D351_BDNA13550
495811,35,,PIK3CA,5290,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"PIK3CA amplification is an infrequent event across cancers (PMID: 28481359), although several individual studies have reported them in lung squamous cell carcinoma, ovarian, esophagus, cervical, and head and neck tumors (PMID: 22960745, 21720365, 25631445, 23636398). PIK3CA gene amplification has been correlated with PIK3CA protein overexpression (PMID: 17992665,19697359). PIK3CA overexpression enhances growth and migration (PMID: 17803655, 26876212). PIK3CA amplifications associate with poor prognosis in several cancers (PMID: 22994622, 22292935, 27095573). Some studies have found a correlation between PIK3CA copy number amplification and sensitivity to PI3K inhibitors (PMID: 24608574, 23136191). Amplification of PIK3CA known pathogenic mutant alleles have also been reported (PMID: 19706770). Expression of this mutation in a patient-derived xenograft model of lung squamous cell carcinoma demonstrated that it was not sensitive to the pan-PIK3CA inhibitor BKM120 similar to PDX models expressing wildtype PIK3CA (PMID: 30093452).",Likely Gain-of-function,"21720365,22960745,17992665,23136191,30093452,19706770,28481359,22292935,22994622,19697359,25631445,24608574,26876212,23636398,27095573,17803655",[],,,,,,[],[],,"PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers.",PIK3CA amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CA-amplified high-grade serous ovarian cancer.,,,[],[],,v4.11,2019-04-18 00:00:00,,M035_pOvaR_DNA5
495812,35,,FGFR3,2261,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.","FGFR3 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR3-amplified high-grade serous ovarian cancer.,,,[],[],,v4.11,2017-01-10 00:00:00,,M035_pOvaR_DNA5
495813,35,,NRG1,3084,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"NRG1, a ligand that binds HER3, is recurrently altered by fusions in lung, pancreatic, and other cancers.","NRG1 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NRG1 deletion high-grade serous ovarian cancer.,,,[],[],,v4.11,2022-07-15 00:00:00,,M035_pOvaR_DNA5
495814,35,,GATA3,2625,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"GATA3 deletions have been detected in patients with breast cancer and commonly results in the production of truncated protein forms (PMID: 15361840). Experimental studies suggest that these mutations alter the cellular localization of the protein (PMID: 15361840), and affects DNA-binding and transactivation abilities (PMID: 7829479, 10935639, 24758297, 26637396) leading to increased cellular invasiveness.",Likely Loss-of-function,"10935639,15361840,26637396,24758297,7829479",[],,,,,,[],[],,"GATA3, a transcription factor, is altered by mutation or amplification in various cancers, most frequently in breast cancer.",GATA3 deletion is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with GATA3 deletion high-grade serous ovarian cancer.,,,[],[],,v4.11,2018-06-01 00:00:00,,M035_pOvaR_DNA5
495815,35,,HRAS,3265,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"HRAS amplification results in overexpression of the protein. This mutation has been found in thyroid, head and neck and small cell lung cancers (cBioPortal, MSKCC, April 2017). Overexpression of HRAS in a rat model of breast cancer and a mouse model of skin cancer demonstrated that this mutation is likely activating as measured by a correlation between increased expression of HRAS and disease progression (PMID: 1855225, 8221670). Overexpression of HRAS is suggested as a potential alternative mechanism for HRAS-mediated oncogenic transformation (PMID: 3283542, 3283542).",Likely Gain-of-function,"3283542,8221670,1855225",[],,,,,,[],[],,"HRAS, a GTPase, is altered in a diverse range of cancers including head and neck squamous cell carcinoma, thyroid, and bladder cancer.",HRAS amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with HRAS-amplified high-grade serous ovarian cancer.,,,[],[],,v4.11,2020-11-16 00:00:00,,M035_pOvaR_DNA5
495816,35,,ETNK1,55500,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"ETNK1, a kinase involved in phospholipid biosynthesis, is recurrently altered by mutation in BCR-ABL negative CML and CMML.","ETNK1 amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ETNK1-amplified high-grade serous ovarian cancer.,,,[],[],,v4.11,2018-08-01 00:00:00,,M035_pOvaR_DNA5
495817,35,,KRAS,3845,Amplification,,,HGSOC,,,,,,,,Likely Oncogenic,"KRAS amplification results in overexpression of the protein. This mutation has been found in germ cell tumors and esophagogastric and ovarian cancer (cBioPortal, Zehir, A et al. Nature Medicine, 2017). In vitro studies have demonstrated that this mutation confers resistance to the tyrosine kinase inhibitor crizotinib, EGFR inhibitors cetuximab or panitumumab, MET inhibitors PHA-665752 or JNJ38877605 and MEK inhibitors AZD6244 or GSK1120212 in patient-derived lung cancer cell line and xenograft models, colorectal cancer cell line models, MET-amplified cell line models and gastric cancer cell line models (PMID: 29808010, 30072474, 23404247, 20841479). Analyses of 475 patients with endometrial cancer demonstrated that KRAS amplification is associated with metastasis (PMID: 23099803).",Likely Gain-of-function,"23099803,29808010,30072474,20841479,23404247",[],,,,,,[],[],,"KRAS, a GTPase which functions as an upstream regulator of the MAPK pathway, is frequently mutated in various cancer types including lung, colorectal and pancreatic cancers.",KRAS amplification is likely oncogenic.,There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KRAS-amplified high-grade serous ovarian cancer.,,,[],[],,v4.11,2021-11-18 00:00:00,,M035_pOvaR_DNA5
495818,35,,ERBB2,2064,Amplification,,,HGSOC,,,,,,,,Oncogenic,"ERBB2 amplification results in overexpression of the protein. Overexpression of ERBB2 in murine fibroblasts and in the mammary glands of genetically engineered mouse models have demonstrated that it is activating as measured by increased pathway activation and tumor growth (PMID: 23204226, 12124352, 11571643, 10716706, 2885917). In vitro studies have demonstrated that this mutation is sensitive to trastuzumab when expressed in biliary tract cancer cell lines as measured by decreased proliferation upon drug treatment (PMID: 30659304). One patient with biliary tract cancer overexpressing ERBB2 had a partial response to an ERBB2-targeting antibody linked to a cytotoxic agent, ado-trastuzumab emtansine (Abstract: Mondaca et al. JCO PO, 2019. https://ascopubs.org/doi/full/10.1200/PO.19.00223). The therapeutic agents trastuzumab, ado-trastuzumab emtansine, lapatinib and pertuzumab in combination with trastuzumab are FDA-approved drugs for the treatment of patients with ERBB2 amplified breast cancer. Trastuzumab is also FDA-approved for the treatment of patients with ERBB2-amplified gastric cancer.",Gain-of-function,"30659304,12124352,2885917,10716706,23204226,11571643","[{'link': 'https://ascopubs.org/doi/full/10.1200/PO.19.00223', 'abstract': 'Mondaca et al. JCO PO, 2019'}]",LEVEL_3B,,,,LEVEL_Fda3,[],[],,"ERBB2, a receptor tyrosine kinase, is altered by mutation, amplification and/or overexpression in various cancer types, most frequently in breast, esophagogastric and endometrial cancers.",ERBB2 amplification is known to be oncogenic.,"While the HER2-targeted antibody trastuzumab is FDA-approved for the treatment of patients with HER2-positive breast and gastric cancers, and the HER2-targeted kinase inhibitor tucatinib in combination with trastuzumab is FDA-approved for patients with HER2-positive colorectal cancer, their clinical utility in patients with HER2-positive high-grade serous ovarian cancer is unknown.",,,[],[],Trastuzumab;Lapatinib;Ado-Trastuzumab Emtansine;Pembrolizumab;Tucatinib;Trastuzumab Deruxtecan;Margetuximab,v4.11,2023-10-16 00:00:00,,M035_pOvaR_DNA5
495819,35,,BCL2,596,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"BCL2, an anti-apoptotic protein, is frequently altered in non-Hodgkin lymphomas.","BCL2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BCL2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.11,2018-01-30 00:00:00,,M035_pOvaR_DNA5
495820,35,,TCF3,6929,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in TCF3 is: Truncating mutations in TCF3 can occur throughout the entire gene and are predicted to lead to loss of its activity (PMID: 29625055). TCF3 encodes a member of the E protein family of helix-loop-helix transcription factors, and it has been shown to be involved in lymphocyte, skin and neural development by regulating the Wnt signaling pathway (PMID: 25990863,17018284, 24832538). Chromosomal translocations involving TCF3 have been shown to be associated with the development of several lymphoid malignancies (PMID: 25729575, 27461063, 31575852). Germline truncating mutations in TCF3 have been shown to lead to severe hypogammaglobulinemia and predispose to B-ALL (PMID: 30063982, 28532655). Additionally, somatic truncating mutations in TCF3 have been identified in patients with several types of carcinomas (PMID: 29625055)",Likely Loss-of-function,"24832538,25729575,30063982,29625055,28532655,17018284,25990863,27461063,31575852",[],,,,,,[],[],,"TCF3, a transcription factor involved in lymphopoiesis, is altered by mutation or deletion in various cancer types.","The TCF3 Deletion is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TCF3 deletion high-grade serous ovarian cancer.,,,[],[],,v4.11,2020-06-14 00:00:00,,M035_pOvaR_DNA5
495821,35,,CEBPA,1050,Amplification,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"CEBPA, a tumor suppressor and transcription factor, is recurrently altered by mutation in acute myeloid leukemia.","CEBPA amplification has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CEBPA-amplified high-grade serous ovarian cancer.,,,[],[],,v4.11,2020-06-20 00:00:00,,M035_pOvaR_DNA5
495822,35,,CRLF2,64109,Deletion,,,HGSOC,,,,,,,,Unknown,,Unknown,,[],,,,,,[],[],,"CRLF2, a cytokine receptor, is recurrently altered by chromosomal rearrangement in B-cell acute lymphoblastic leukemia.","CRLF2 deletion has not specifically been reviewed by the OncoKB team, and therefore its biological significance is unknown.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CRLF2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.11,2018-02-14 00:00:00,,M035_pOvaR_DNA5
495823,35,,ZRSR2,8233,Deletion,,,HGSOC,,,,,,,,Likely Oncogenic,"The mutation effect description for truncating mutations in ZRSR2 is: ZRSR2 truncating mutations result in several forms of C-terminally truncated protein. These mutations are found in myelodysplastic syndrome and are predominantly found in male patients given the location of ZRSR2 on the X chromosome (PMID: ). Knockdown of ZRSR2 in HEK293T cells showed aberrant splicing and global intron retention, showing the importance of ZRSR2 in the splicing of U12-type introns. Knockdown of ZRSR2 in human hematopoietic stem cells showed reduced proliferation and colony formation but also showed defects in differentiation. Together this suggests that loss of ZRSR2 may contribute to defective differentiation due to splicing defects (PMID: 25586593).",Likely Loss-of-function,25586593,[],,,,,,[],[],,"ZRSR2, a splicing factor,  is altered in various hematological malignancies.","The ZRSR2 Deletion is a truncating mutationZRSR2, and therefore is likely oncogenic.",There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ZRSR2 deletion high-grade serous ovarian cancer.,,,[],[],,v4.11,2018-12-10 00:00:00,,M035_pOvaR_DNA5
